THE UNIVERSITY OF BRITISH COLUMBIA€¦ · UBC CME Program: Update on the Dementia Syndrome – January 18, 2003 17. Vancouver General Hospital: Neuroscience Grand Rounds – September

1

THE UNIVERSITY OF BRITISH COLUMBIA

S192- 2211 Wesbrook Mall Vancouver, BC, V6T2B5

Curriculum Vitae for Faculty Members

Date completed: June 8, 2013

1. SURNAME: FELDMAN FIRST NAME: HOWARD MIDDLE NAME(S): 2. DEPARTMENT/SCHOOL: Medicine 3. FACULTY: Medicine 4. PRESENT RANK: Full Professor SINCE: July 1, 2001 5. POST-SECONDARY EDUCATION

University or Institution Degree Subject Area Dates

McGill University DCS Arts 1971-1973 McGill University MDCM Medicine 1974-1978 University of British Columbia FRCP(C) Neurology 1984-1986

PROFESSIONAL QUALIFICATIONS Internship - University of Western Ontario 1978-9

Victoria Hospital - London, Ontario Residency Training

Internal Medicine - McGill University 1981-83 Royal Victoria Hospital - Montreal, Quebec Neurology - University of Colorado 1983-84 Neurology - University of British Columbia 1984-86 Fellowship Training

Amyotrophic lateral sclerosis and Neuromuscular Diseases -1986 University of British Columbia Supervisor – Dr. A.A. Eisen Fellowships Awarded

Fellow of the Royal College of Physicians and Surgeons of Canada FRCP (Neurology) 1986 Fellow of the Canadian Academy of Health Sciences FCAHS (2008 – present)

Fellow of the American Academy of Neurology FAAN (2008 – present)

2

6. EMPLOYMENT RECORD (a) At UBC

RANK OR TITLE

Dates Executive Associate Dean, Research UBC Faculty of Medicine

January 2012- present

Full Professor UBC Division of Neurology

2001-present

Head UBC Division of Neurology

2001- 2008

Ralph Fisher and Alzheimer Society of B.C. Endowed Professor in Alzheimer Research

2007 – 2008, 2012- present

Director Clinic for Alzheimer Disease & Related Disorders : UBC Hospital

2005- 2008, 2013

Clinical Associate Professor

1996 – 2001

Clinical Assistant Professor

1991 – 1996

Clinical Instructor

1987-1991

Attending Neurologist, UBC Hospital and Vancouver General Hospital, Vancouver

Active Staff 1993 - present

Attending Neurologist UBC and Shaughnessy Hospital

Active Staff 1988 -1993

Attending Neurologist – UBC Alzheimer Clinic Director UBC Alzheimer Clinical Trials Program

1989 - present 1991 - present

Attending Neurologist – UBC Head Injury

1992 - 1999

3

Program Director of UBC Head Injury Program

1995 – 1999

(b) Other University Appointments

Adjunct Professor McGill University 1995 to present - McGill Center for Studies in Aging Adjunct Clinical Professor Yale University, New Haven CT, USA 2010 to present

(c) Leaves from UBC and other employment

January 1, 2009 – December 31, 2011: Granted leave from UBC to take on position of Vice-President and Therapeutic Area Head Neuroscience, Global Clinical Research and Development, Bristol-Myers Squibb, Wallingford Connecticut, USA. During this leave from UBC, I undertook the challenge of a leadership position in global clinical neuroscience drug development program at Bristol-Myers Squibb. Responsibilities in this role included the development and evolution of the Neuroscience research strategy as well as leading the clinical global research programs across Neurology and Psychiatry. This career opportunity supported the acquisition of important insights into the advancement/translation of academic insights in the development of new medicines for Alzheimer’s disease, neuropathic pain, autism, depression, schizophrenia and migraine.

TEACHING OF HEALTH CARE PROFESSIONALS ROUNDS (Specialty, Grand Rounds Vancouver & UBC)

1. UBC Department of Medicine CME Event: Medicine in the 21st Century – June 5, 2008 2. Riverview Hospital: Geriatric Psychiatry Update, UBC Division of Geriatric Psychiatry – November 23, 2007 3. UBC Department of Medicine CME Event: Medicine in the 21st Century – June 14, 2007 4. Vancouver General Hospital: Geriatric Psychiatry Grand Rounds – April 16, 2007 5. Vancouver General Hospital: Neurosciences Grand Rounds – March 21, 2007 6. Vancouver General Hospital: Geriatric Medicine Grand Rounds – February 7, 2007 7. Vancouver General Hospital: Geriatric Psychiatry Grand Rounds – January 29, 2007 8. St. Paul’s Hospital: CME (Vancouver, BC) – November 17, 2006 9. Vancouver General Hospital: Radiology Rounds – November 23, 2005 10. Vancouver General Hospital: Neurosciences Grand Rounds – September 14, 2005 11. Mount St. Joseph’s Hospital: Geriatric Team (Vancouver, BC) – May 31, 2005 12. Vancouver Hospital: Geriatric Medicine Rounds – April 26, 2005 13. Vancouver General Hospital: Geriatric Psychiatry Outreach Team Rounds – February 14, 2005 14. Mount St. Joseph’s Hospital: Rounds (Vancouver, BC) – October 12, 2004 15. St. Paul’s Hospital: CME (Vancouver, BC) – October 31, 2003 16. UBC CME Program: Update on the Dementia Syndrome – January 18, 2003 17. Vancouver General Hospital: Neuroscience Grand Rounds – September 4, 2002 18. Vancouver General Hospital: Specialty Noon Rounds, Neurology – August 2, 2002 19. UBC Department of Medicine Noon Specialty Rounds July 25, 2003 20. UBC Department of Medicine Course: Medicine in the 21st Century – June 5, 2003 21. UBC Department of Medicine Grand Rounds – July 11, 2002 22. UBC Clinical Neuroscience Grand Rounds – March 27, 2002 23. Riverview Hospital: Geriatrics Day – November 16, 2001 24. St. Paul’s Hospital: 47th Annual Family Practice Course (Vancouver, BC) – October, 2001 25. Riverview Hospital: Department of Psychiatry Grand Rounds – September 26, 2001 26. UBC Hospital: Clinical Teaching Unit Rounds – September 4, 2001 27. UBC Department of Medicine Course: Medicine in the 21st Century – June 21, 2001

4

28. Burnaby Hospital: Department of Family Practice Grand Rounds (Burnaby, BC) – April 3, 2001 29. St. Vincent’s Hospital: Geriatric Grand Rounds (Vancouver, BC) – January 16, 2001 30. UBC Outreach CME Conference (via televideo) – September 29, 2000 31. St. Vincent’s Hospital: Rounds (Vancouver, BC) – May 30, 2000 32. UBC Department of Medicine Resident Teaching Rounds – January 11, 2000 33. UBC Department of Medicine Resident Teaching Rounds – August 6, 1999 34. UBC Clinical Neurosciences Grand Rounds – May 5, 1999 35. St. Vincent’s Hospital: Geriatric Psychiatry Grand Rounds (Vancouver, BC) – May 11, 1999 36. St. Vincent’s Hospital: Geriatric Psychiatry Grand Rounds (Vancouver, BC) – September 8, 1998 37. UBC Clinical Neurosciences Grand Rounds – September 4, 1998 38. UBC Department of Medicine Grand Rounds – November 21, 1996 39. UBC Clinical Neurosciences Grand Rounds – November 13, 1996 40. St. Vincent’s Hospital: Geriatric Psychiatry Grand Rounds (Vancouver, BC) – November, 1996 41. UBC Clinical Neurosciences Grand Rounds – November 22, 1995 42. St. Vincent's Hospital: Geriatric Medicine Rounds (Vancouver, BC) – February 28, 1995 43. UBC Department of Family Practice Rounds – November, 1994

Non-UBC Rounds (in Canada):

44. Royal Jubilee Hospital: Stroke Rounds – May 12, 2008 45. Vernon Hospital Rounds (Vernon, BC) – October 25, 2007 46. Langley Memorial Hospital: Grand Rounds (Langley, BC) – May 31, 2007 47. Foothills Hospital (Calgary, AB) – November 24, 2005 48. Peace Arch Hospital: Family Practice Grand Rounds (White Rock, BC) – May 9, 2005 49. Queen’s Park Care Centre, Dept. of Geriatrics Grand Rounds (New Westminster, BC) – April 7, 2005 50. McGill University, Dept. of Geriatrics Grand Rounds, Jewish General Hospital (Montreal) – June 4, 2004 51. University of Montreal, Department of Geriatrics Grand Rounds, Hospital Notre Dame – June 3, 2004 52. University of Toronto Baycrest Geriatric Institute, Dept. of Psychiatry, Toronto, ON – November 14, 2003 53. University of Alberta, Div. of Geriatric Medicine Grand Rounds, Glenrose Hospital – September 24, 2002 54. University of Calgary, Department of Clinical Neurosciences, Grand Rounds – September 6, 2002 55. University of Sherbooke, Division of Geriatric Medicine Grand Rounds, Institut de Geriatrie – May 2, 2002 56. University of Montreal, Department of Neurology Grand Rounds, Notre Dame Hospital – May 2, 2002 57. McGill University Alzheimer Disease Research Unit, Jewish General Hospital (Montreal) – May 1, 2002 58. Kelowna General Hospital: Department of Family Practice Grand Rounds – May 16, 2001 59. University of Western Ontario, Dept Psychiatry Grand Rounds, London Psychiatric Hospital – February 16, 2001 60. University of Manitoba, Section of Neurology, Neurosciences Grand Rounds – February 15, 2001 61. University of Toronto, Division of Geriatric Psychiatry, Journal Club (Toronto, ON) – February 13, 2001 62. University of Manitoba, Health Sciences Centre: Memory Disorders Clinic – February 15, 2001 63. North Bay Psychiatric Hospital: Televideo Conference (North Bay. Ontario) – February 13, 2001 64. Dalhousie University, Divs. of Geriatrics/Neurology Grand Rounds, QEII Health Sci. Ctr. – Dec. 13, 2000 65. St. Joseph’s Hospital: Geriatric Grand Rounds (St. John, New Brunswick) – December 12, 2000 66. University of Alberta, Div. Geriatric Medicine Grand Rounds, Glenrose Hospital, Edmonton AB Nov 7, 2000 67. Victoria Hospital: Department of Geriatric Medicine Grand Rounds (Victoria, BC) – June 7, 2000 68. University of Manitoba, Dept. of Psychiatry & Neurology Rounds, St. Boniface Hospital – March 3, 2000 69. Victoria General Hospital: Department of Family Practice, Grand Rounds – January 11, 1994

Non-UBC Rounds (outside of Canada):

70. Yale University: Department of Neurology Grand Rounds (New Haven, CT) – May 22, 2013 71. Columbia University: Department of Neurology Grand Rounds (New York, NY) – April 3, 2012 72. Georgetown University: Department of Neurology Rounds (Washington, DC) – January 31, 2008 73. Northwest Hospital (Seattle, WA) – January 20, 2006 74. Dean Medical Centre: Department of Neurology Grand Rounds (Madison, WI) – March 18, 2005 75. University of Virginia: Department of Neurology Grand Rounds (Charlottesville, VA) – December 17, 2004 76. Maine Medical Centre: Department of Neurology Grand Rounds – March 18, 2004 77. Brown University: Rhode Island Hospital Department of Neurology Grand Rounds – March 17, 2004 78. St. Joseph’s Hospital Grand Rounds Pontiac, Michigan – December 19, 2003

5

79. St. Mary’s Medical Centre (Los Angeles, CA) – March 14, 2003 80. UCLA Cedars Sinai Medical Centre: Psychiatry Grand Rounds (Los Angeles, CA)– March 13, 2003 81. St. Joseph’s Hospital: Department of Neurology Grand Rounds (Phoenix, AZ) – February 7, 2003 82. Case Western Reserve University Hospital of Cleveland Neurology Grand Rounds – January 23, 2003 83. University of Oklahoma: Department of Neurology Grand Rounds – November 8, 2002 84. University of Maryland: Department of Neurology Grand Rounds – October 11, 2002 85. Northwestern University: Alzheimer Disease Research Centre – June 14, 2002 86. Baylor University: Department of Neurology Grand Rounds – March 8, 2002

CONTINUING EDUCATION ACTIVITIES SCIENTIFIC/ACADEMIC CONFERENCE PARTICIPATION (Organizer, Keynote Speaker, Invited Research Presentations)

1. Alzheimer’s Association International Conference 2013; Boston MA July 13, 2013; Alzheimer’s Imaging

Consortium; The role of neuroimaging in AD drug development; invited panelist 2. One Mind for Research: 2nd Annual Meeting; Baltimore MD, May 14-15, 2013; The Global Agenda for

Alzheimer’s disease dementia: Invited speaker and session chair 3. Frontotemporal Dementia and AD Related Taupathies: Bethesda MD; May 1-2, 2013; NIH Alzheimer’s

Disease and Related Dementias Workshop: Invited panellist 4. Alzheimer Disease International Annual meeting Tapei, Taiwan April 2013; Debate on future success of

treatment for Alzheimer’s disease, Invited presenter 5. Key Symposium on Clinical Trials in Alzheimer’s disease, Stockholm, Sweden, December 2012: Clinical

trials in predementia AD, Invited Presenter 6. Canadian Association of Gerontology, Vancouver BC, October 2012: Alzheimer’s Disease Update: Invited

Plenary lecture 7. 4th Latin American Cognitive Impairment Meeting, Buenos Aires, Argentina, May 2012 Invited Lectures 8. NIH Summit on Frontotemporal Dementia Washington DC June 2012; Meeting discussant and closing

summary 9. Alzheimer Society of Manitoba Annual Meeting 2012; Winnipeg MA, March 2012; Alzheimer disease update

Plenary lecture 10. 1st Annual Alzheimer Association of Saudi Arabia Conference on Alzheimer’s Disease: February 2012;

Invited Lecturer 11. World Congress of Neurology: Marrakesh Morocco November 14, 2011 Symposium on Most Important

Publications in Neurology, Invited Presenter 12. World Congress of Neurology: Marrakesh Morocco November 15, 2011 Symposium on Pathogenesis of

Cognitive Impairment in Dementia, Invited Presenter 13. World Congress of Neurology: Marrakesh Morocco November 16, 2011 Symposium on New Treatments in

Neurology, Invited Presenter 14. Clinical Trials in Alzheimer’s Disease (CTAD): San Diego USA November 5, 2011 Symposium on

Frontotemporal Dementia, Clinical Trials, Invited Speaker and Member of the Scientific Committee 15. Canadian Conference on Dementia: Montreal October 29, 2011 Invited Plenary Speaker 16. Human Amyloid Imaging, Miami Fl; January 13-15, 2011; Invited Plenary Speaker 17. Phacilitate CNS Leaders Forum Boston, MA, USA November 10, 2010 Invited Speaker 18. 3rd International Conference on Clinical Trials in Alzheimer’s Disease (CTAD) Toulouse France November

5, 2010 Invited Speaker, Session Chair and Member of the Scientific Committee 19. 13th International Conference on Alzheimer’s Disease (ICAD) Honolulu Hawaii USA July 2010; Symposium

Speaker Institute of Medicine 20. 2nd Conference on Clinical Trials in Alzheimer’s Disease (CTAD), Las Vegas USA – October 29-30, 2009;

Invited Speaker 21. Enabling Technologies for Alzheimer’s Disease Research, Bar Harbour ME- August 6-7, 2009 Invited

Speaker 22. 12th International Conference on Alzheimer’s Disease (ICAD), Vienna, Austria – July 13, 2009; Invited

Speaker 23. 3rd International Research Workshop of Cognition in Amyotrophic Lateral Sclerosis – June 21-23, 2009

London Ontario; Invited Speaker 24. Alzheimer Association Research Roundtable: Alzheimer Disease Classification – April 1-2, 2009

Washington DC Invited Speaker 25. 1st Brazilian Alzheimer Specialists Meeting (Sao Paolo, Brazil) – Dec 6, 2008; Invited Speaker

6

26. Meeting of the International Society for CNS Clinical Trials and Methodology (Toronto, ON) – Oct 6-7, 2008; Invited Speaker & Co-chair

27. Canada-China Workshop on Aging Research (Vancouver, BC) – Sep 24, 2008; Invited Speaker 28. Geriatric Psychiatry and Neurology Symposium (Seoul/Busan, Korea) – Sep 20-22, 2008; Invited Speaker 29. First Conference on Clinical Trials on Alzheimer’s Disease (Montpellier, France) – Sep 17-19, 2008; Invited

Speaker & Session Chair 30. European Congress of Neuropsychopharmacology: Symposium on Alzheimer’s Disease (Barcelona,

Spain) – Sep 1, 2008, Session Chair and invited speaker 31. 12th Congress of the European Federation of Neurological Societies (Madrid, Spain) – Aug 23-26, 2008;

Poster Presenter 32. Alzheimer’s Iberoamerican Congress (Buenos Aires, Argentina) - Aug 6-8, 2008; Invited Speaker 33. Canadian Federation of Neurological Sciences Teaching Course at the CNSF 43rd Annual Congress

(Victoria, BC) – June 20, 2008; Speaker and Course Chair 34. 16th Tel-Aviv University AD Conf. “The Blanche Prince Lecture” (Tel-Aviv, Israel) – June 16, 2008; Invited

Speaker 35. European Neurological Society 18th Annual Meeting (Nice, France) – June 7-11, 2008; Teaching Course Co-

Chair & Invited Faculty 36. UBC Dept. of Psychiatry 7th Annual Clinical Day (Vancouver, BC) – May 30, 2008; Keynote Speaker 37. UC San Diego ADRC Annual Conference on AD. (San Diego, CA) – May 22, 2008; Invited Speaker 38. Alzheimer Society of Canada “Dementia Continuum Mapping Forum” (Toronto, ON) – May 2, 2008; Invited

Participant 39. Alzheimer’s Assoc. Research Roundtable “Scales as Outcome Measures for AD Clinical Trials” Mtg.

(Washington, DC) – April 29-30, 2008; Invited Speaker 40. Novartis Neuroscience Symposium “Touching the future of dementia” (Copenhagen, Denmark) – April 25,

2008; Invited Speaker 41. 5th International Pharmacoeconomic Conf. on AD (Newark, NJ) – March 29, 2008; Invited Speaker 42. UBC Canadian-Dutch Dementia Colloquium (Vancouver, BC) – March 26-27, 2008; Chair 43. 10th Int. Hong Kong/Springfield Pan-Asian Symposium on Advances in AD Therapy (Hong Kong) –

February 28-March 1, 2008; Invited Speaker 44. 2nd Annual BC Psychopharmacology Conf. (Vancouver, BC) – February 16, 2008; Invited Speaker 45. 2nd Ntl. Symposium (Maastricht, Netherlands) – February 14, 2008; Invited Speaker 46. American Academy of CME: Dementia Forum (Modesto, CA) – January 12, 2008; Invited Speaker 47. 5th Int. Vascular Dementia Congress (Budapest) – November 8-11, 2007; Symposium Chair & Invited Faculty 48. 4th Canadian Colloquium on Dementia (Vancouver, BC) – October 18-20, 2007; Mtg. Co-chair & Speaker 49. 5th Philippine Conf. on ADRD; Dementia Society of the Philippines (Manila) – October 12, 2007; Invited

Speaker 50. 4th Int. Neurology Forum (Ho Chi Minh City) – July 6-7, 2007; Invited Faculty 51. 17th Mtg. of the European Neurological Society (Rhodes, Greece) – June 17, 2007; Teaching Course Co-

chair & Invited Faculty 52. 2nd Int. Research Workshop on FTD in ALS (London, ON) – June 13, 2007; Invited Speaker 53. North Shore Health Research Foundation Dinner (North Vancouver, BC) – May 24, 2007; Invited Keynote 54. Alzheimers Ntl. Conf. (Wellington, New Zealand) – April 26-28, 2007; Chair & Invited Keynote 55. 5th Annual MCI Symposium (Miami, FL) – April 13-14,2007; Invited Discussant 56. American Assoc. of Geri. Psychiatry Annual Mtg. (New Orleans) – March 2-4, 2007; Invited Chair & Speaker 57. Int. Symposium Fundacion Ramon Areces (Madrid, Spain) – November 15, 2006; Invited Speaker 58. 28th Ntl. Conf. of Alzheimer Society of Canada (Toronto) – November 6, 2006; Invited Plenary Speaker 59. 5th Annual Dementia Congress (Orlando, FL) – November 4, 2006; Invited Speaker 60. Atorvastatin Global Investigator’s Mtg. IV (Boston, MA) – October 6, 2006; Invited Speaker 61. 10th Congress of European Federation of Neurosciences (Glasgow, UK) – September 3, 2006; Invited

Speaker 62. 10th Int. Conf. on ADRD, Madrid, Spain – July 18, 2006; Invited Plenary Address 63. 41st Mtg. of Canadian Congress of Neurological Sciences (Montreal) – June 17, 2006; Invited Speaker 64. 9th Int. Geneva/Springfield Symposium (Geneva, Switzerland) – April 19, 2006; Invited Speaker 65. American Academy of Neurology Geriatric Neurology Section Mtg. (San Diego, CA) – April 4, 2006 66. 19th Annual American Assoc. of Geriatric Psychiatry (Puerto Rico) – March 12, 2006; Invited Speaker 67. 4th Kuopio Symposium (Helsinki, Finland) – February 3, 2006; Invited Speaker 68. 1st Annual Dementia Research Day, BC Network for Aging Research (Vancouver, BC) – January 26, 2006 69. Alzheimer Disease: Defining Therapeutic Success (Rome, Italy) – November 11, 2005 70. World Congress of Neurology (Sydney, Australia) – November 5, 2005; Teaching Courses

7

71. 3rd Canadian Colloquium on Dementia (Ottawa, ON) – October 27, 2005; Mtg. Co-chair 72. 18th European College of Neuropsychopharmacology (Amsterdam, NL) – October 24, 2005 73. 4th Int. Congress on Vascular Dementia (Porto, Portugal) – October 21, 2005; Organizer & Symposium Chair 74. Int. Psychogeriatric Assoc. (Stockholm, Sweden) – September 21, 2005 75. European Federation of Neurosciences (Athens, Greece) – September 18, 2005; Symposium Chair & Invited

Speaker 76. Karolinksa Institute (Sundsvall, Sweden) – September 17, 2005; Invited Speaker 77. Novartis Foundation Mtg. (London UK) – July 22, 2005; Invited Speaker 78. 40th Mtg. of the Canadian Congress of Neurological Sciences (Ottawa, ON) – June 16, 2005 79. American Assoc. of Geriatric Psychiatry (Atlanta, GA) – May 25, 2005; Invited Speaker 80. Alberta Research Consortium for AD Symposium (Edmonton, AB) – May 20, 2005; Invited Speaker 81. 1st Int. Consensus Congress on Non-Pharmacological Therapies for AD (Madrid) – May 13, 2005; Member

Scientific Committee & Invited Speaker 82. 1st Annual North Pacific Aging & Dementia Symposium (Washington DC) – April 15, 2005; Program

Committee & Invited Speaker 83. 18th Annual American Assoc. for Geriatric Psychiatry (San Diego, CA) – March 4-6, 2005; Invited Speaker 84. 3rd Annual Congress of Dementia (San Juan, Puerto Rico) – February 25-27, 2005; Invited Speaker 85. Int. Neuropsychological Society (St. Louis, MI) – February 2-4, 2005; Invited Speaker 86. Int. Psychogeriatric Assoc. Expert Conf. on MCI (Washington, DC) – January 20-22, 2005; Invited Speaker 87. 2nd Canadian Conf. on Antidementia Drug Guidelines – October 28-30, 2004; Convener & Chair 88. 20th Alzheimer’s Disease International Mtg. (Kyoto, Japan) – October 16, 2004; Invited Speaker 89. 9th Int. Conf. on ADRD (Philadelphia, PA) – July 22, 2004; Invited Speaker 90. 39th Annual Mtg. of the Can. Congress of Neurological Sciences (Calgary) – June 9, 2004; Invited Speaker 91. 3rd Congres National les Unites de Soins Alzheimer (Toulouse, France) – May 3, 2004; Invited Speaker 92. 56th Annual Mtg. of the American Academy of Neurology (San Francisco) – April 26, 2004; Teaching Course 93. 8th Int. Montreal/Springfield Symposium (Montreal, PQ) – April 16, 2004; Invited Speaker 94. Euro. Alzheimer Consortium-US Alzheimer Consortium Mtg. (Montreal, PQ) – April 4, 2004; Invited Speaker 95. American Medical Directors Assoc. Annual Mtg. (Phoenix, AZ) – March 03, 2004; Invited Speaker & Session

Chair 96. 2nd Canadian Colloquium on Dementia (Montreal, PQ) – October 18, 2003; Mtg. Co-chair & Invited Speaker 97. 3rd Int. Workshop on Dementia with Lewy Bodies & Parkinson’s Disease Dementia (Newcastle-upon-

Tyne, UK) – September 18, 2003; Session Co-chair & Invited Speaker 98. 2nd Annual Dementia Congress (Washington, DC) – September 12, 2003; Invited Speaker 99. European Federation of Neurosciences (Helsinki, Finland) – September 2, 2003; Invited Speaker 100. 13th Alzheimer Europe & 3rd Greek AD Mtg. (Thessaloniki, Greece) – June 13-14, 2004; Invited Speaker &

Chair 101. American Geriatric Society Annual Scientific Mtg. (Baltimore, MA) – May 17, 2003; Invited Speaker 102. 25th Annual Alzheimer Society of Canada Conf. (Ottawa, ON) – April 11, 2003; Invited Plenary Speaker 103. Global Aricept Investigator’s Mtg. (Key Biscayne, FL) – February 3, 2003; Invited Speaker 104. Les Unités de Soins Alzheimer, 2ème Congrès Ntl. (Paris, France) – December 13, 2002; Invited Speaker 105. Int. Psychogeriatric Assoc. Special Expert Conf. on Dementia with Lewy Bodies (Budapest, Hungary) –

November 22, 2002; Invited Speaker & Section Chair 106. Alzheimer’s Disease International Conf. (Barcelona, Spain) – October 25, 2002; Invited Speaker 107. FTD & Pick’s Disease Conf. (London, ON) – September 15, 2002; Invited Speaker 108. UCLA Los Angeles Dementia Mini-Fellowship (Los Angeles, CA) – August 17, 2002; Invited Speaker 109. 3rd Pharmacoecomonical Conf. on AD (Stockholm, Sweden) – July 20, 2002; Invited Speaker 110. Geneva Springfield International Conf. on AD (Geneva, Switzerland) – April 5, 2002; Invited Speaker 111. Dementia Forum (Rome, Italy) – March 16, 2002: Invited Speaker 112. Int. College of Neuropsychopharmacology Inaugural Mtg. (Hawaii, USA) – December 14, 2001; Invited

Speaker 113. 1st Canadian Colloquium on Dementia (Toronto, ON) – October 13, 2001; Co-convener & Invited Speaker 114. 8th Int. Psychogeriatric Assoc. (Nice, France) – September 12, 2001; Symposium Chair & Invited Speaker 115. 6th Int. Assoc. of Gerontology Mtg. (Vancouver, BC) – July 2001; Symposia Chair & Invited Speaker 116. 23rd Annual Alzheimer Society of Canada Conf. (Halifax, NS) – April 6, 2001; Invited Speaker 117. 8th Banff Conf. Therapeutic Advances in Neurology & Neurosurgery – February 3, 2001; Invited Speaker 118. Aricept Global Investigators Mtg. (Orlando, FL) – January 8-12, 2001; Mtg. Co-Chair & Speaker 119. 1st Conf. on Quality Research in AD (London, UK) – November 19, 2000; Invited Speaker 120. Canadian Academy of Geriatric Psychiatry Annual Mtg. (Victoria, BC) – October 4, 2000; Invited Speaker 121. Emerging Therapeutics for Dementia (Gold Coast, Australia) – July 29-30, 2000; Invited Speaker

8

122. BC Medical Assoc. 2000 Congress (Victoria, BC) – June 30, 2000; Invited Speaker 123. 6th Int. Stockholm/Springfield Symposium (Stockholm, Sweden) – April 8, 2000; Invited Speaker 124. Maximising the ABC of Dementia, Crete 2000 (Heraklion, Greece) – March 10, 2000; Workshop Chair 125. Mount Elizabeth Hospital Dept. of Medicine Grand Rounds (Singapore) – November 23, 1999 126. Mtg. of the Malaysian Assoc. Geriatric Psychiatry (Kuala Lumpur) – November 21, 1999; Invited Speaker 127. Lecture Tour of Taiwan Taichung (Kaushing, Taipei) – November 18-20, 1999; Invited Speaker 128. Korean Assoc. for Geriatric Psychiatry (Seoul, Korea) – October 1, 1999; Invited Speaker 129. Seoul National University Dept. of Neurology Grand Rounds (Seoul, Korea) – September 30, 1999; Invited

Speaker 130. St. Luke’s Medical Centre Annual Course on Geriatrics (Manila, Philippines) – September 28, 1999; Invited

Speaker 131. Mtg. of the Philippines Neurological Assoc., (Manila, Philippines) – September 27, 1999; Invited Speaker 132. Forefronts in Neurology (Whistler, BC) – September 25, 1999; Invited Speaker 133. Cochrane Collaborator’s CDCIG Annual General Mtg. (Vancouver, BC) – August 21, 1999; Invited

Participant 134. 9th Int. Psychogeriatric Assoc. Congress (Vancouver, BC) – August 19, 2000; Invited Speaker 135. Current Concepts in MCI (Chicago, IL) – June 24, 1999; Invited Speaker 136. Canadian Congress of Neurological Sciences Annual Mtg. (Edmonton) – June 1999; Invited Speaker 137. Victoria Neuroscience Symposium (Victoria, BC) – May 1999; Invited Speaker 138. Dementia 1999 (Vancouver, BC) – April 1999; Invited Speaker 139. AD: Current Developments, Future Strategies Int. Symposium (Barcelona, Spain) – March 1999; Invited

Speaker 140. Society of Psychiatrists of South Africa Annual Mtg. (Johannesburg) – September 1998; Speaker 141. 6th Int. Conf. on ADRD (Amsterdam, Netherlands) – July 1998; Invited Speaker 142. 59th Annual North Pacific Society of Neurology, Neurosurgery & Psychiatry Mtg. (Tacoma, WA) – April

1998; Speaker 143. 20th Alzheimer Society of Canada National Conf. (Vancouver, BC) – April 1998; Invited Speaker 144. Dementia 1997 Conf. (Vancouver, BC) – October 1997; Invited Speaker 145. Canadian Assoc. of Gerontology (CME) – October 1997; Invited Speaker 146. World Congress Neurology (Buenos Aires, Argentina) – September 1997; Invited Speaker 147. 13th Alzheimer Disease International Conf. & 7th Annual European Mtg. (Helsinki, Finland) – September

1997; Invited Speaker 148. BC Assoc. of Community Care Annual Conf. (Kelowna, BC) – June 1997; Invited Speaker 149. 58th Annual Mtg. of the North Pacific Society of Neurology (Victoria, BC) – May 1997; Invited Speaker 150. Memorial University Dept. of Medicine/Neurology (St. John’s, Newfoundland) – December 1996; Visiting

Speaker 151. 31st Annual Can. Congress of Neurol. Sci. (London, ON) – June 1996; Symposium Chair & Invited Speaker 152. American College of Physicians Biennial Int. Medicine Review (Vancouver BC) – June 1996; Invited

Speaker 153. BC Assoc. of Neuropsychologists (Vancouver, BC) – April 1996; Invited Speaker 154. Dalhousie University Visiting Lecturer (Halifax, Nova Scotia) – April 1996; Invited Speaker 155. Riverview Hospital AD Symposium (Port Coquitlam, BC) – January 1996; Invited Speaker 156. Int. Working Group, Harmonization of Antidementia Drug Guidelines (London, UK) – September 1995;

Chair & Invited Speaker 157. Annual Mtg. of the Canadian Academy of Geriatric Physicians (Victoria, BC) – September 1995; Invited

Speaker 158. 30th Annual Can. Congress of Neurol. Sci. (Victoria BC) – June 1995; Symposium Chair & Invited Speaker 159. Riverview Hospital AD Symposium (Port Coquitlam, BC) – January 1995; Invited Speaker 160. Helen Kanee Memorial Lecture, Louis Brier Hospital (Vancouver, BC) – September 1994; Invited Speaker 161. Western Can. AD Experts Conf. (Whistler, BC) – March 1994; Symposium Chair & Invited Speaker 162. Consortium of Can. Ctrs. for Clinical Cog. Res (C5R), Montreal, PQ – October 1993; Chair & Invited Speaker 163. Royal College of Physicians & Surgeons Canada Annual Mtg. (Vancouver, BC) – 1993; Invited Speaker 164. Riverview Hospital AD Symposium (Vancouver, BC) – June 1993; Invited Speaker 165. Consortium of Can. Ctrs. for Clinical Cog. Res. (C5R) (Ottawa, ON) – May 1993; Chair & Invited Speaker 166. Colorado Neurological Institute (Denver, CO) – September 1992; Invited Speaker 167. Society of Nuclear Medicine Annual Mtg.: Pacific Northwest Chapter Symposium – 1992; Invited Speaker

9

(h) MEMBERSHIP ON SCIENTIFIC COMMITTEES AND WORKING GROUPS

1. Frontotemporal Dementia Study Group Steering Committee 2010-present 2. US Alzheimer Association Research Roundtable (Chair) 2010- 2012

3. US EU Task Force on Designing Trials for Prevention of Alzheimer’s Disease 2010 4. US EU Task Force on Designing Clinical Trials for Predementia Alzheimer’s Disease – 2009 5. NIA- Alzheimer Association Working Group on Diagnostic Criteria for MCI - 2009-2010 6. Industry Advisory Committee for Autosomal Dominant Alzheimer’s Disease Therapeutic Trials - 2010

(i) VISITING PROFESSORSHIPS

1. Chinese University of Hong Kong: January 16, 2008; Visiting Professor – Department of Psychiatry 2. University of California (Irvine): May 9-10, 2006; Visiting Professor – Department of Neurology 3. University of Virginia (Charlottesville): December 17, 2004; Visiting Professor – Department of Neurology 4. Wayne State University (Detroit): July 8-9, 2004; Visiting Professor – Department of Neurology 5. University of Michigan (Ann Arbor): December 17-18, 2003; Visiting Professor – Department of Neurology 6. Universita di Milano (Milan, Italy): June 3-5, 2003; Visiting Professor – Department of Neurology 7. University of Ottawa (Ottawa ON): January 16, 2002; Visiting Professor – Division of Geriatric Medicine 8. University of Manitoba (Winnipeg): February 15, 2001; Visiting Professor – Depts. of Neurology & Psychiatry

(k) DISSERTATION COMMITEE AND EXAMINATIONS (M.Sc., Ph.D.)

1. Dr. Yvonne Freund-Levi: June 13, 2008; Opponent for dissertation at Karolinska Institute, Stockholm, Sweden 2. Fidel Vila-Rodriguez, PhD: 2007-8; Research Topic: Translational research of Apo-E proteomics via

quantification of Apo-E in human brain tissue from various conditions including AD, Schizophrenia, and aging 3. Dalia Tanaka Gottlieb, PhD: 2004 – 2006; PhD in Graduate Studies: Dementia and Creativity 4. Jeffrey Helm, Experimental Medicine, MSc – 2000 – 2002; Research Topic: Inflammatory Regulation of

Alzheimer’s Disease (l) ADMINISTRATION RELATED TO TEACHING (National or local, course or curriculum planning, curriculum innovation, residency committee)

1. Canadian Colloquium on Dementia Steering Committee 2013 2. Canadian Colloquium on Dementia Co-Chair (biannual national program): 2003, 2005, 2007 3. Clinical Neurosciences Grand Rounds Committee Chair: 2001 – 2008 4. UBC Site Coordinator of Undergraduate Dept. of Medicine Teaching Program: July 1995 – July 1997 5. UBC Site Program Coordinator for Neurology Rotation for Core Internal Med. Residents: Oct. 1993 – 1997 6. Neurology Residency Training Committee, Executive: October 1995 – 2008

(m) PUBLICATIONS/LECTURES ON TEACHING METHODS OR CURRICULUM

1. Feldman H.: Lecture slides on Alzheimer’s disease – Diagnosis and Management; 2001 2. Feldman H. & Foti D.: Lecture slides for Brain and Behaviour – Cognitive Assessment; 1999 3. Feldman H.: Dementia lecture note series in Neurology (for UBC medical students) UBC Dept. Medicine; 1994 4. Feldman H.: Altered States of Consciousness. Lecture note series in Neurology, Dept. of Med.; 1991, 1994

(n) EVALUATION OF INSTRUCTIONAL ACTIVITIES - Supplied by Faculty Member i) Data from non-UBC sponsored CME evaluation forms ii) Publications and/or professional achievements of graduate students and research fellows

10

7. TEACHING DOSSIER (a) PRIOR TO JULY 1, 2001 PERCENTAGE OF TIME DEVOTED TO: (i) 10% lecturing-other teaching

(ii) 15% clinical instruction (iii) 30% research/publication (iv) 15% administration (v) 30% clinical practice (vi) 0% other (specify)

(b) JULY 1, 2001- DECEMBER 2008 PERCENTAGE OF TIME DEVOTED TO: (i) 5% lecturing-other teaching


(c) SINCE JANUARY 3, 2012 PERCENTAGE OF TIME DEVOTED TO: (i) 10% lecturing-other teaching, advancing new initiatives


(d) NON-CLINICAL INSTRUCTION: Classroom instruction (lectures, courses, dates, number of students enrolled). Provide titles and number of hours. (teaching dossier can be provided upon request)

Undergraduate Teaching:

Course

Scheduled Hours

Class Size

Hours Taught

(a) Lectures 3/12/08 Brain and Behaviour

AD Treatment strategies: Theory & Practice

1 175 1 hour

2/6/08 Brain and Behaviour

AD Treatment strategies: Theory & Practice

2 175 2 hours


Alzheimer Disease: Treatment strategies from theory to practice

1 175 1 hour


Higher Cortical Function: Theory and Practice

2 175 2 hours

3/8/06 Brain & Behaviour

Alzheimer disease: treatment strategies, theory and practice

1 175 1 hour


Clinical Higher cortical function

2 175 2 hours

3/8/06 Alzheimer disease: 1 175 1 hour

11

Course

Scheduled Hours

Class Size

Hours Taught

Brain & Behaviour

treatment strategies, theory and practice

6/4/05 OSCE examination 5 125 5 hours 3/2/05 Brain & Behaviour

Treatment Strategies: From Theory to Practice

2 125 2 hours


Clinical Higher Cortical Function

2 125 2 hours

3/11/04 INDE 420

Cranial Nerve Exam: Bedside

4 8 4 hours


AD Treatment strategies: theory & practice

1 125 1 hour

2/12/04 INDE 420

Higher Cortical Function: Bedside

4 8 4 hours


Cognitive Function: Clinical 2 125 2 hours


Cognitive Function: Clinical 2 125 2 hours

1/30/03 INDE 420 Brain & Behaviour

Cranial Nerve Exam: Bedside

3 8 3 hours


Motor and Sensory: Bedside

3 8 3 hours


Cognitive Function from Theory to Practice

1 125 1 hour

3/7/01 Brain & Behaviour FMED 426

Treatment Strategies of Alzheimer’s Disease – Theory & Practice

1 125 1 hour


Higher Cortical Function 2 125 2 hours


Higher Cortical Function 2 125 2 hours

2/25/99 Introduction to Neurolinguistics

Audiology 402 2 30 2 hours


Treatment Strategies Theory & Practice

1 125 1 hour


INDE 420 Cranial Nerves

4 6 4 hours

3/13/98 Introduction to Neurolinguistics


1997 Brain & Behaviour


3/21/97 Neurosciences Course Med. II

Anatomy 425/510 2 120 2 hours

3/7/96 Neurosciences Course Med. II

Anatomy 425/510 2 120 2 hours

1995 Audiology 402 4 30 4 hours

12

Course

Scheduled Hours

Class Size

Hours Taught

Brain & Behaviour 1994 Brain & Behaviour


1993 Brain & Behaviour


(b) Seminars

Course

Scheduled Hours

Class Size

Hours Taught

4/25, 5/2, 5/9, 5/16 2008 Clinical Skills Teaching

INDE 420 3.5 6 Total 14 hours (3.5 hours per

session)

5/26/03 Neurology

Bedside Teaching Clinical Clerks

2 4 2 hours

1/29/01 Neurology

Phase IV Clinical Clerkships

2 20 2 hours

1/14/01 Clinical Skills

INDE 420 3.5 6 3.5 hours

2/4/00 Clinical Skills Teaching

INDE 420 3.5 6 3.5 hours

1/31/00 Neurology

Phase IV Clinical Clerkships

2 20 2 hours

1/29/00 Clinical Skills Teaching

INDE 420 Cranial Nerves

4 6 4 hours

1/21/00 Brain & Behaviour Week 4

INDE 420 3.5 6 3.5 hours

February 1999 Clinical Skills

Seminar Series 2 2 4 2 hours

February/March 1990-1998 Medi 450

Seminar Series Neurology 4 sessions

2 4 2 hours per session

December/January 1990-1998 Medi 450

Seminar Series 3 sessions


February/March 1990-1998



9/98 Memory & Modernism

English 539A 2 30 2 hours

2/96 Advances in Neurology

Medi 450 2 10 2 hours

(c) Bedside Teaching

Course

Scheduled

Hours

Class Size

Hours taught

May 13,2008 Neurology Bedside 2 4 2 hours

13

Teaching January 22, 2008

Neurology Bedside Teaching


May 12, 2007 2-Year Objective Structured Clinical Examination

7.5 7.5 hours

June 2, 2007 1-Year Objective Structured Clinical Examination

5.5 5.5 hours

March 13, 2007

3-Year Medical Student Bedside

3.5 4 3.5 hours

February 6, 2007



January 9, 2007



May 3, 2005 Neurology Bedside Teaching


September 21, 2004



July 13, 2004 Neurology Bedside Teaching


February 14, 2003 Neurology Bedside Teaching


December 2001 3rd year clinical clerks Neurology Specialty


December 2000 Phase IV Neurology Specialty Clinics


January 2000 Phase IV Neurology Specialty Clinics


1998

Neurology Specialty Clinics UBC Hospital 2 sessions


December/January 1994-1997

Neurology Specialty Clinics UBC Hospital 3 sessions


December/January 1994-1997

General Medicine 8 sessions

1.5 4 1.5 hours per session

1993-1997

UBC Hospital Oral Examinations

3 3 hours

1990-1993 Examination

Shaughnessy Hospital 6 sessions


1990-1993 Shaughnessy Hospital 6 sessions


1993-1997 UBC Hospital Neurology Specialty Clinics 4 sessions


February/March 1990-1998



September 1998 Memory & Modernism

English 539A 2 30 2 hours

February 1996 Advances in Neurology

Medi 450 2 10 2 hours

Post Graduate Teaching:

Course Scheduled Class Size Hours Taught

14

Hours July 17 & 24, 2008 Neurology resident teaching

academic half day lectures: Screening testing for cognition

1 24 Total 2 hours (1 hour per

session)

February 22-23, 2007

Seminar for Thailand Neurologists Dementia and Memory Disorders Units for Optimal Care

14 7 14 hours

February 27, 2007 Seminar for Psychiatry Residents Journal Club on AD2000 Study

2 15 3 hours

February 8, 2007 Teaching to Psychiatry Residents: The Dementias Part II

2 15 2 hours

November 23, 2006 Neurology resident teaching academic half day lectures: Update on Cortical Syndrome

1 20 1hour

May 18, 2006 Neurology resident teaching academic half day lectures: Approach to Cortical Syndrome

1 20 1hour

August 4 & 18, 2005 Neurology resident teaching academic half day lectures: MSE

2 20 2 hours

September 30, 2004 Final year psychiatry residents – New insights into the diagnosis and neurobiology of dementia

2 20 2 hours

March 27, 2003

Graduate Studies: Neuroscience 501 Neurobiology of dementia

1 20 1 hour

February 28, 2002 Medi 540 Advances in Dementia Experimental Medicine

2 6 2 hours

May 26, 2001 Main Pro C Course

A Learning Program on AD and other Dementias for Family Physicians

7 12 7 hours

April 12, 2001 Academic Half Day Lecture Neurology Residents

Neurology Resident Basic Science Seminar

1 10 1 hour

June 25 – 30, 2001 Preceptorship Training Dr. Lloyd Singham, Nedlands, Australia. Training at UBC Alzheimer Clinic

28 1 28 hours

January 18, 2001 Academic Half-Day Lecture

Towards an Understanding of Alzheimer’s Disease Part 1

1 10 1 hour

March 29, 2001 Medi 450 Experimental Medicine Advances in Alzheimer’s disease

2 6 2 hours

March 19, 2001 Medi 450 Experimental Medicine

4 30 4 hours

15

October 14, 2000 University of Calgary Main Pro C Course CME Alzheimer Disease

2 20 7 hours

December 19, 2000 Preceptorship Dr. Bertolucci & associates from Sao Paulo, Brazil – Alzheimer’s Disease Training at UBC Alzheimer Clinic

4 7 7 hours

1998 (Ongoing) Primary Care Physicians Dementia Preceptorship Training at UBC Alzheimer Clinic

2-3 7 7 hours

July 1991 UBC Division of Geriatrics - Seminars for Fellows: SPECT scanning in dementia

1 4 1 hour

May 1991 UBC Division of Geriatrics - Seminars for Fellows: Acute and chronic confusional states

1 4 1 hour

1990 CME UBC Faculty of Medicine Dawson Creek: Neurology Update

3 6 3 hours

(e) RESEARCH SUPERVISION (students, research fellows, visiting scientists)

Student Name

Program Type Year Principal Co-Supervisor(s) Start End

Amir Sephery PhD Neuroscience January 2011 Dr. C. Jacova Dr. P. Lee Dr. L. Beattie Dr. R. Hsiung Dr. H. Feldman

Itthipol Tawankanjana-chot

Clinical/Clinical Research Fellowship – Pacific Alzheimer Research Foundation (PARF)

August 2008 July 2010 Dr. H. Feldman Dr. C. Jacova Dr. R. Hsiung Dr. P. Lee

Umamon Puangthong

Clinical Fellowship November 2007

November 2009

Dr. H. Feldman Dr. C. Jacova

Nagaendran Kandiah

Clinical/Clinical Research Fellowship

July 2007 July 2008 Dr. H. Feldman Dr. C. Jacova

Eleonora Locatelli

Clinical/Clinical Research Fellowship

July 2007 October 2007 Dr. H. Feldman Dr. R. Hsiung Dr. P. Lee

16

Noah Silverberg

Post Doctoral Fellowship – Michael Smith Foundation for Health Research (MSFHR) (awarded but declined)

n/a n/a Dr. H. Feldman Dr. B. Hallam

Giuseppe Iaria Alzheimer Society of Canada – Post Doctoral Fellowship

2007 2009 Dr. H. Feldman Dr. J. Barton

Giuseppe Iaria Post Doctoral Fellowship – Michael Smith Foundation for Health Research (MSFHR)

2007 2009 Dr. J. Barton Dr. H. Feldman

Amanda LaMarre

Senior Graduate Trainee Award – Michael Smith Foundation for Health Research (MSFHR)

2006 2008 Dr. H. Feldman Dr. B. Hallam Dr. K. Christoff

Joyce Yeo Clinical and Clinical Research Fellowship (Geriatrics) Manchester UK

January 2006 December 2006

Dr. H. Feldman

Dalia Tanaka Gottlieb

PhD in Graduate Studies (UBC)

2005 April 2006 R. Irwin Dr. H. Feldman

Dr. Claudia Jacova

Post Doctoral Fellowship – Canadian Institutes of Health Research (CIHR) Training Award in Neurobiology and Behaviour – Michael Smith Foundation for Health Research (MSFHR)

January 2005 July 2007 Dr. H. Feldman

Dr. Najeeb Qadi

Clinical and Clinical Research Fellowship (Neurology) Saudi Arabia

March 2005 July 2007 Dr. H. Feldman Dr. R. Hsiung Dr. D. Foti Dr. L. Beattie Dr. P. Lee

Dr. Michael Woodward

Clinical and Clinical Research Fellowship (Melbourne Australia)

January 2005 June 2005 Dr. H. Feldman

17

Leila Shobab Undergraduate Kinesiology (Simon Fraser University) Directed Study II

January 2004 May 2004 Dr. H. Feldman Dr. C. Krieger

Brennan Eadie

MSc in Neuroscience Directed Study

July 2003 December 2003

Dr. H. Feldman Dr. C. Jacova

Leila Shobab Undergraduate Kinesiology (Simon Fraser University) Directed Study I

January 2003 May 2003 Dr. H. Feldman Dr. C. Krieger

Dr. Anastasia Dressler

Clinical Research Fellowship Fondazione Stella Maris, University of Pisa, Italy

April 2003 May 2003 Dr. H. Feldman Dr. L. Beattie

Dr. Inge Loy-English

Clinical Fellowship University of Ottawa

February 2003 April 2003 Dr. H. Feldman Dr. D. Foti Dr. L. Beattie

Dr. Robin Hsiung

Post Doctoral Fellowship a) Michael Smith Foundation for Health Research (MSFHR) b) West Coast Energy Alzheimer Award

July 2002 July 2004 Dr. H. Feldman Dr. L. Field

Dr. Robin Hsiung

MSc in Epidemiology (UBC)

December 2000

December 2001

Dr. A. Levy (Epidemiology)

Dr. H. Feldman

Dr. Ronald Scholes

Clinical and Clinical Research Fellowship (Melbourne, Australia)

March 2001 September 2001

Dr. H. Feldman

Jeffrey Helm MSc in Neuroscience (UBC)

July 2000 September 2001

Dr. D. McLarnon (Pharmacology)

Dr. H. Feldman

Dr. Kevin Peters

PhD in Cognitive Psychology (UBC)

September 1999

June 2003 Prof. P. Graf (Psychology)

Dr. H. Feldman Dr. S. Hayden

Dr. Jeff Politsky

Neurology Resident Research Project (UBC)

February 1998 April 1999 Dr. H. Feldman

Dr. Mun-Seong Choi

Clinical Fellowship (Pusan, Korea)

September 1997

September 1998

Dr. H. Feldman

18

Jeff Oyler

Medical Student Yr. IV Research Project

September 1995

December 1995

Dr. H. Feldman

Dr. Virginia Devonshire

Neurology Resident Research Project

December 1994

January 1996 Dr. H. Feldman Dr. D. Anderson

Andre Mattman

Summer Medical Student UBC Faculty of Medicine

June 1994 December 1995

Dr. H. Feldman

(f) RESEARCH MENTORING (students, research fellows, visiting scientists)

Faculty Name

Program Type Year Principal Co-Supervisor(s)

Dr. Haakan Nygaard

Junior Faculty Mentoring Yale University

2011 Present Dr. H Feldman

Dr. Philip Lee

Faculty of Medicine Mentoring Program

2005 2009 Dr. H. Feldman

8. SCHOLARLY AND PROFESSIONAL ACTIVITIES

(a) AREAS OF SPECIAL INTEREST AND ACCOMPLISHMENTS Summary of Research Interests and Accomplishments in Dementia and Cognitive Disorders

In 1991, in the early part of my career, I established a clinical research unit focused on cognitive disorders and aging (the UBC Alzheimer Clinical Research Program). Its breadth of activity has developed to include research on healthy aging, geriatric cognitive disorders, Alzheimer’s disease (AD) and other dementias particularly the frontotemporal dementias. This unit has grown from a small core to a well recognized interdisciplinary group that has been recognized as a leading international centre for clinical cognitive research. It has provided research and clinical fellowship training opportunity for neurologists and psychiatrists from around the world, as well as all level of studentship training. It has successfully seen a number of its fellows and post docs advance to academic faculty positions. It has focused on a) Epidemiological and Longitudinal Research Studies: b) Experimental Therapeutics and Clinical Trials: c) Research on Frontotemporal Dementia (FTD): d) Development of Biological Markers for Dementia: e) Development of Novel Instruments for Research:

19

Major scientific contributions: The elucidation of the genetics of frontotemporal dementia and amyotrophic lateral sclerosis with discoveries of the progranulin and C9ORF72 gene mutations and TDP 43 as well as delineation of the early stages of Alzheimer’s stage (predementia/prodromal) with development of novel diagnostic criteria and the development of the first clinical trials in the predementia/prodromal AD stage .

Other Positions Held: US Alzheimer Association Research Roundtable (Chair) 2010-2012

Ralph Fisher and Alzheimer Society of BC Endowed Professorship in Alzheimer’s Research September 2007 to 2009 and 2012 to present Director UBC Head Injury Assessment Program May 1995 - 1999

President Canadian Consortium of Centers for Clinical Cognitive Research 1995-97 (b) RESEARCH or EQUIVALENT GRANTS

(indicate under COMP whether grants were obtained competitively (C) or non-competitively (NC) GRANTS APPLIED FOR (Under Review) – Updated March 27, 2013

Granting Agency Subject COMP Total $ Yr(s) Principal Invest.

Co-Invest.

W. Garfield Weston Foundation

PHINEAS- NHL: Past Head Injury Effects on Aging Study: National Hockey League Alumni

Comp Team Grant

TBD C. Wellington

H Feldman (co-PI) GYR Hsiung A Thornton W Panenka + 9 Alzheimer Alzheimer and Cerebrovascular research centers

W. Garfield Weston Foundation

Alzheimer’s disease, amyloid-β, epitope, active immunotherapy, vaccine, natural antibodies, oligomers

Comp Team Grant

TBD N Cashman H Feldman (co-PI) J Araujo H Chertkow SA Halperin GYR Hsiung D Munoz A Potter C Wellington

Brain Canada Chagnon Family Team Grant

Advancing multimodal interventions to improve everyday function in those at risk of dementia/Alzheimer’s disease

Comp Team Grant

$8.1 Million 2013-2018

H Feldman GYR Hsiung C Jacova C Wellington T Liu Ambrose G Payne O Benavente, T Field + 8 Alzheimer and Cerebrovascular research centers

20

SALARY and AWARDS - Updated February 28, 2013

Granting Agency Candidate and Level of

Training COMP Total $ Yr(s) Principal

Supervisor Co-Supervisor

Michael Smith Foundation for Health Research (MSFHR)

Noah Silverberg (Post Doctoral Fellowship) Topic: Social Cognition in FTD (awarded but declined)

Comp $40,000

07-09 H Feldman B Hallam

Alzheimer Society of Canada

Giuseppe Iaria (Post Doctoral Fellowship) Topic: Visuospatial Mapping in MCI and AD (awarded and accepted)

Comp $40,000

07- 09 H Feldman

Michael Smith Foundation for Health Research (MSFHR)

Giuseppe Iaria (Post Doctoral Fellowship) Topic: Visuospatial Mapping in MCI and AD (awarded and accepted)

Comp $40,000

07- 09 J Barton H Feldman

COMPETITIVE GRANTS (Currently Held or Completed) - updated:February 28, 2013

Granting Agency Subject COMP Total $ Yr(s) Principal

Invest. Co-Invest.

Canadian Institutes of Health Research (CIHR) Application # 287674

Clinical, Pathological, Genetic and Biomarker studies of Frontotemporal Dementia

Comp $1,615,915 2013-18 I Mackenzie Principal Applicant

H Feldman Principal Investigator (CoPI)

Canadian Institutes of Health Research (CIHR)

Development of a Computer-Based Screening Test to Support Evaluation of Cognitive Impairment and Dementia

Comp $50,000 09-10 C Jacova G-YR Hsiung J McGrenere BL Beattie H Feldman

British Columbia Ministry of Health

Treatment Response Study: The Clinical Meaningfulness in Alzheimer Disease Treatment (CLIMAT) Scale

Comp $350,000 2008-12 C Jacova H Feldman (through Oct 2008)

Canadian Institutes of Health Research (CIHR) (# 00725-000)

Canadian Dementia Knowledge Translation Network (CDKTN)

Comp $3,540,000 2008-12 K Rockwood

H Feldman H Chertkow J Keefe J LeClair

21

Canadian Institutes of Health Research (CIHR) – Research Net (# 179009)

Frontotemporal Lobar Degeneration with Ubiquitinated Inclusions: Genetic, Clinical, Pathological and Biomarker Studies

Comp $1,585,540 2008-13 H Feldman (Principal Applicant through 2009)

I Mackenzie (co PI and Principal applicant from 2009) R Hsiung B Hallam C Jacova K Raheru J Stoessl T Ruth

Canadian Institutes of Health Research (CIHR) (#178403)

Sleep and Cognition in Aging

Comp $453,550 08-13 C Smith K Peters H Feldman

VGH & UBCH Foundation (In It For Life)

Development of a Clinical Meaningfulness in AD Treatment (CLIMAT) Scale

Comp $29,780 07-08 H Feldman C Jacova

Pacific Alzheimer Research Foundation (PARF) (Centre Grant C06-01)

Overlap Syndromes Resulting in Dementia

Comp $5,757,300 07-12 J Stoessl

H Feldman I Mackenzie V Sossi D Doudet T Ruth & Mayo Clinic Jacksonville Co-Investigators

Canadian Institutes of Health Research (CIHR)

Maintenance of University of British Columbia PET Scanners

Comp $665,000 06-11 T Ruth H Feldman D Doudet R Durand V Sossi J Stoessl S Withers D Yapp L Yatham

Canada Foundation for Innovation (CFI) – Leading Edge Fund

Brain Research Centre: A Platform for Basic and Translational Neuroscience

Comp $6,812,616 06-09 M Cynader H Feldman & Brain Research Centre Co-Investigators

Networks of Centres of Excellence (NCE)

PrioNet Canada

Comp $20,936,268 05-09 N Cashman H Feldman

National Institutes of Health (NIH) (USA) (# 1 U01- AG24904-01)

Alzheimer’s Disease Neuroimaging Initiative (ADNI)

Comp $352,245 05-09 M Weiner L Thal Center PI: H Feldman

R Hsiung

Canadian Institutes of Health Research (CIHR) (# 74580)

Frontotemporal Dementia with Ubiquinated Inclusions

Comp $674,739 05-08 H Feldman

I Mackenzie (Co PI) R Hsiung B Leavitt N Cashman B Hallam K Rabheru D Sadovnick

22

Michael Smith Foundation for Health Research (MSFHR) & Canadian Institutes of Health Research (CIHR)

Strategic Training Program in Neurobiology and Behaviour

Comp $300,000 02-07 S Vincent H Feldman (mentor in program)

Canadian Institutes of Health Research (CIHR) (# 73376)

Preventing AD & Related Dementias

Comp $50,000 05-06 H Feldman M Schulzer

Canadian Institutes of Health Research (CIHR) Institute on Aging

2nd Canadian Conference on Anti-dementia Drug guidelines

Comp

$10,000 2004 H Feldman S Gauthier


CSHA-BC Cohort Linkage: Characterization, prediction and costs of Health Services

Comp $107,515 02-04 BL Beattie H Feldman G Gutman C Hertzman

VGH & UBCH Foundation

A Serial Magnetic Resonance Study of Cognitively-Impaired-Not-Demented Patients and Controls

Comp $38,638 02-04 H Feldman DKB Li

Alzheimer Society of Canada & Canadian Institutes of Health Research (CIHR)

A Serial Magnetic Resonance Study of Cognitively-Impaired-Not-Demented Patients and Controls

Comp

$90,477 02-04 H Feldman BL Beattie D Foti S Hayden DKB Li

National Institute of Health (NIH) (USA)

Mild Cognitive Impairment Comp

$156,000

99-03 H. Feldman (Center PI) R Petersen (Study PI)

R Baker D Foti BL Beattie J Beckman

Canadian Institutes of Health Research (CIHR) & NHRPD

Canadian Study of Health and Aging III

Comp $275,715 (Vancouver center)

02-03 I McDowell BL Beattie H Feldman G Gutman D Sadovnick

MRC-PMAC Program (# 14197)

A Cohort Study of Cognitive Impairment and Dementia Syndromes with the Development of a Consortium Registry ACCORD Study

Comp $288,000 Per annum for 8 sites ($36,000/ site)

97-02 H Feldman D Sadovnick I McKenzie BL Beattie & C5R investigators at 7 centres


Apolipoprotein E genotyping The Canadian Study of Health and Aging

Comp $20,800 99-00 D Sadovnick

H Feldman

MRC-PMAC Program

Vascular Dementia Diagnostic Criteria and Outcomes (CIVIC study)

Comp $268,420 Per annum for 8 sites ($33,000/ Site)

96-99 K Rockwood

H Feldman A Kertesz R Bouchard S Gauthier S Black D Hogan

BC Health Research Foundation

BC Cohort linkage study Comp $19,000 97-98 BL Beattie H Feldman C Hertzman G Gutman A Donald

23

NHRDP; MRC, Pfizer and Bayer

A Canadian Study of Health and Aging II

Comp $514,486 95-98 I McDowell BL Beattie H Feldman & CSHA multicentre investigators

NHRDP Canadian Study of Health and Aging II. Follow-up

Comp $5 million total for multicentre study

90-93 I McDowell BL Beattie H Feldman & CSHA investigators

NON- COMPETITIVE GRANTS (Currently Held or Completed) - updated: Aug 12, 2012

Elan Pharmaceuticals

ELND 005 A Randomized Clinical Trial of Efficacy and Safety

NC Clinical

Trial

$260,000 2008 H Feldman D Foti BL Beattie R Hsiung P Lee

Lundbeck Canada Inc.

Development Study of a Clinical Meaningfulness in AD Treatment (CLIMAT) Scale

NC $40,780 07-08 H Feldman C Jacova

Myriad, Ltd. Randomized Double Blind Placebo Controlled Trial of Flurizan in the Treatment of Mild Severity AD

NC Clinical

Trial

$228,480 06-08 H Feldman Site PI

D Foti BL Beattie J Beckman R Hsiung P Lee

Glaxo Smith Kline

A 54-week, RCT study to investigate the effects of rosiglitazone as adjunctive therapy to AChEIs on cognition and overall clinical response in APOE4 stratified subjects with mild to moderate AD

NC Clinical

Trial


D Foti BL Beattie J Beckman R Hsiung P Lee

ONO (# ONO-2506-POU010)

A double-blind, phase II, safety & efficacy evaluation of ONO-2506PO in subjects with mild to moderate Alzheimer's disease

NC Clinical

Trial

$315,000 05-07 H Feldman Site PI & Steering Committee Member

R Baker D Foti BL Beattie J Beckman R Hsiung

Servier (# CL2-18986-009)

Efficacy of 15mg of S 18986 on Cognitive Symptoms in Mild Cognitive Impairment patients treated over a 12-month oral administration period

NC Clinical

Trial

$120,925 05-07 H Feldman Site PI & Country PI


Rx & D Eisai Pfizer Lilly Janssen (#86128)

ACCORD II: A longer term assessment of cognitive impairment and dementia syndromes with evaluation of treatment effectiveness

NC Cohort Study

$598,000 04-06 H Feldman PI

A Levy I Mackenzie S Hayden D Sadovnick BL Beattie+ C5R investigators at 7 centres

24

Sanofi-Synthelabo (# LTS-5283)

Long-term safety extension of phase II study EFC5286 of SR57667B in subjects with mild-to-moderate Alzheimer’s disease

NC Clinical

Trial



Sanofi (# EFC5286)

A phase II, multicentre, multinational, randomised, double-blind, placebo controlled, efficacy, safety & tolerability study of SR57667B in patients with mild-to-moderate AD

NC Clinical

Trial



Pfizer (# A2581078)

LEADe study: Donepezil and Atorvastatin in the treatment of mild to moderate AD

NC Clinical

Trial

$150,000

03-05 H Feldman Site PI

R Baker BL Beattie J Beckman D Foti R Hsiung

Glaxo Smith Kline (# ALDHD- 2001/00013/01)

Multi-Site Collaborative Study for Genotype-Phenotype Associations in Alzheimer's Disease: GenADA Study

NC Clinical

Trial

$275,480 02-05 H Feldman Site PI & Head Steering Committee

R Baker BL Beattie J Beckman D Foti R Hsiung

Janssen Galantamine in Mild Cognitive Impairment

NC Clinical

Trial

$180,000

01-04 H Feldman Site PI & Steering Committee


Neotherapeutics

Evaluation of neotrofin in the treatment of mild to moderate AD – open label Phase 2B

NC Clinical

Trial



Neotherapeutics

Evaluation of neotrofin in the treatment of mild to moderate AD – open label

NC Clinical

Trial



Janssen Evaluation of galantamine in the treatment of vascular dementia

NC Clinical

Trial



Novartis ENA-INT-01 Exelon open label study of mild to moderate AD

NC Clinical

Trial



Boehringer Ingleheim

An evaluation of talsaclidine in the treatment of mild to moderate Alzheimer’s disease

NC Clinical

Trial

$60,000 98-99 H Feldman Site PI & Steering Committee member


Bayer M.I.N.T. Metrifonate in the treatment of Alzheimer’s disease

NC Clinical

Trial



Hoescht Marion Roussel

An evaluation of Propentofylline for the treatment of AD and VaD

NC Clinical

Trial



25

Pfizer Donepezil Hydrocholoride in the treatment of moderate to severe AD

NC Clinical

Trial

$150,000 97-98 H Feldman Site PI & Lead Investigator


Janssen An evaluation of Galantamine in the treatment of mild to moderate Alzheimer’s disease

NC Clinical

Trial



Eisai Evaluation of the safety and efficacy of E2020 in patients with mild to moderate Alzheimer’s disease

NC Clinical

Trial

$200,00

96-97 H Feldman Site PI

J Beckman A Hill

Hoffman LaRoche Moclobemide in the treatment of Alzheimer’s disease

NC Clinical

Trial

$125,000

96-97 B Carlton H Feldman

Sandoz Prospective, randomized, parallel-groups, placebo-controlled study to evaluate the efficacy, safety and tolerability of individually optimal doses of SDZ ENA 713 given bid or tid in out-patients with mild to moderate probable Alzheimer disease

NC Clinical

Trial

$227,000 95-97 H Feldman Site PI & Study PI

J Beckman R Baker BL Beattie

Smith Kline Beecham

A randomized double-blind, placebo controlled dose-ranging study of the efficacy and tolerability of SB202926 in patients suffering from dementia of the Alzheimer's type

NC Clinical

Trial

$90,000 95 -96 H Feldman Site PI & Steering Committee Member

J Beckman BL Beattie R Baker

Janssen Canadian Caregiver Survey of Service Utilization

NC Clinical

Trial

$3,700 94-96 H Feldman PI

Janssen SAB-Int 12, Evaluation of Sabeluzole in the Treatment of Alzheimer Disease

NC Clinical

Trial

$250,000 94-96 H Feldman Site PI & Lead Study Author

BL Beattie J Beckman R Baker

Hoffman Laroche The development of a functional rating scale for drug therapy in A.D.

NC Clinical

Trial


BL Beattie

Hoffman Laroche Lazebamide in the treatment of Alzheimer’s disease

NC Clinical

Trial

$308,000 93-94

H Feldman Site PI

BL Beattie

DuPont Pharma DUP996 in mild to moderate Alzheimer’s disease

NC Clinical

Trial


BL Beattie

26

9. SERVICE TO THE UNIVERSITY (a) Memberships on committees, including offices held and dates

1. Child and Family Research Institute: Board Member: 2012 -present 2. UBC Faculty of Medicine Dean’s Executive Committee: 2012 - present 3. UBC Faculty of Medicine Executive Committee: 2007-2009, 2012 - present 4. UBC Dept. of Medicine Executive Committee: 2001 - 2009 5. Search Committee for Head of UBC Dept. of Psychiatry: 2006 6. Search Committee for Head of UBC Division of Geriatric Medicine: 2004 7. UBC and VH Brain and Spinal Cord Research Centre – Research Clinical Committee: 1997 - present. 8. UBC Dept. of Medicine Academic Appointments, Reappointments, Promotions & Tenure Committee:

1997-2001

10. SERVICE TO THE ACADEMIC COMMUNITY (a) Memberships on scholarly societies, including offices held and dates

1. Canadian Neurological Society: Secretary Treasurer 2007 - 2009 2. International College of Geriatric Psychoneuropharmacology: Founding member 2002 - present 3. Consortium of Canadian Centres for Clinical Cognitive Research (C5R): Executive Committee Member

1992-1995; President 1995 – 1997; Past President 1997-1999 4. International Working Group on Harmonization of Dementia Drug Guidelines (IWG): Executive Committee

Member 1995 - present; Chair, Translations Committee 1995 - present 5. International Society for Vascular Behavioural & Cognitive Disorders (Vas-Cog): Founding member 2002-

present 6. Institute for the Study of Aging (ISOA): Member, Scientific Review Board 2002 - present 7. Alzheimer Disease International: Member, Scientific and Medical Advisory Board 1998 - present 8. Eur. Institute of Women’s Health: Member, Int. Expert Adv Committee on Alzheimer’s Report 1998-present 9. American Academy of Neurology: Member, Nominating Committee for Officers of Geriatric Neurology 1998 -

1999 10. American Academy of Neurology: Section of Neurogeriatrics; Member of Education & Liaisons Committee 11. Canadian Congress of Neurological Services: Active Member 1997 - present 12. American Academy of Neurology: Active Member 1986 – 2008, elected Fellow 2009 13. ALS Society of British Columbia: Board Member 1986 - 1988; Advisory Board Member 1988 – 1990

(b) Memberships on other societies, including offices held and dates

1. Alzheimer Society of Canada: Chair of the Biomedical Peer Review Panel – January 2012 to present 2. Canadian Institutes of Health Research (CIHR): Biological and Clinical Aspects of Aging 2005 – 2007 3. Royal College of Physicians & Surgeons: Member, Core Nucleus Committee for Neurology 2002 - 2007

(c) Memberships on Scientific Committees and Boards, including dates 1. BC Health Research Strategy; Steering Committee Member 2012 to present 2. Canadian Dementia Knowledge Translation Network: Theme leader 2007-2009, Member of National Advisory

Board 2009-2012 1. New York Academy of Science/One Mind Research: A Translational Science Initiative for Alzheimer’s and

Diseases with Dementia; Co-Chair Leadership Council January 2012-present 2. National Institute on Aging (US) Advisory Panel on prevention of dementia trial with ASA: September 2007 3. International Clinical Trial of MPC 7869 in the Treatment of AD: Member, Data Safety Monitoring Board

October 2003 - 2006; Sponsor – Myriad Pharmaceuticals 4. RIS 232 Clinical Trial of Risperidone in the Treatment of Dementia: Chair, Data Safety Monitoring Board

December 2001 - March 2003; Sponsor – Johnson and Johnson 5. InDDEX Study: International Clinical Trial of Rivastigmine for Mild Cognitive Impairment: Chair, Diagnosis

Monitoring Committee 1999 - 2004; Sponsor – Novartis Pharmaceuticals

27

6. International Clinical Trial of Dehydroepiandrosterone for Alzheimer’s Disease: Chair, Data Safety Monitoring Board 1997-1999; Sponsor - Neurocrine Pharmaceuticals

(d) Editorships

1. Journal of Neurological Sciences (2002 - 2012): Editorial Board 2. Dementia and Geriatric Cognitive Disorders (2002 - 2009): Editorial Board 3. Brain Aging (2001 - 2008): Editorial Board 4. Geriatrics Canada (Journal of the Canadian Geriatrics Society) (2001 - 2005): Editorial Board 5. Research and Practice in Alzheimer’s Disease (2001 - 2008): Associate Editor 6. International Psychogeriatrics (2000 - 2003): Associate Editor 7. Canadian Alzheimer’s Review (1997 - present): Editorial Board 8. Alzheimer’s Digest (1997 - 1999): Editor in Chief 9. Health over 50 (1997 - 1998): Editorial Board

(e) Reviewer (journal, agency, etc.. including dates)

1. EU Joint Programme Neurodegenerative Disease (JPND) 2013; 2. US National Institutes on Aging: Invited External Reviewer, 2013 3. Canada Research Chairs and Canadian Foundation of Innovation UBC Faculty of Medicine: review panel

chair 2012-present 4. Child and Family Research Institute Investigator Award Reviewer: 2012-2013 5. Margolese Prize in Cardiac and Neurosciences: Chair Review Panel 2012-2013 6. Canadian Institute of Health Research: Invited Reviewer, September 2005 - present 7. University of Manitoba, Section of Neurology: External Reviewer, January 2004 8. Canadian Institutes of Health Research (CIHR): External Reviewer, 2001 - present 9. Institute for the Study of Aging (ISOA): Review Board, 2002 - present 10. Alberta Heritage Foundation for Medical Research: External Reviewer, 2001 - present 11. US Alzheimer’s Association: External Reviewer, 2000 - present 12. Medical Research Council of Canada: External Reviewer, 1997 - 1999 13. Workers’ Compensation Board Review Panels: 1992 - 2004 14. Alzheimer Society of Canada - Review Board: Claude Beaubien Prize, 1993 - 1994 15. Alzheimer Society of Canada - Biomedical Peer Review Panel: Internal Reviewer (1993 - 1995); External

Reviewer (1995 - present) (f) Journal Reviewer: Ad hoc reviewer for

1. New England Journal of Medicine: 2. Cortex: 3. Nature Clinical Practice Neurology: 4. Lancet Neurology: 5. Archives of Neurology: 6. Archives of General Psychiatry: 7. Drugs and Aging: 8. Journal of Internal Medicine: 9. Journal of Neurology, Neurosurgery and Psychiatry: 10. Alzheimer Disease and Associated Disorders: 11. American Journal of Geriatric Psychiatry: 12. Journal of the Neurological Sciences: 13. Dementia & Geriatric Cognitive Disorders: 14. Neurology: 15. Canadian Journal of Neurological Sciences: 16. International Journal of Geriatric Psychiatry: 17. Drug Information Reference, 5th Edition: 18. Annals of Neurology: 19. Stroke: 20. Canadian Journal of Aging: 21. International Psychogeriatrics: 22. Canadian Medical Association Journal:

28

23. Journal of Psychiatry and Neuroscience: 24. Canadian Journal of Pharmacology: 25. Parkinsonism and Related Disorders:

(g) Consultant (indicate organization and dates)

1. Synapse Technologies Ltd.: 1998 - May 2001 2. Forbes Medi-Tech: 1999 - Present 3. Active Pass: 1999 – Present 4. Immune Network: 1999 - Present 5. Pharmaceutical companies: 1995 - 2008

Consultant on Advisory Boards and on design, methodology and data analyses of RCTs. Including Bristol Myers Squibb, Pfizer, Eisai, Janssen, Servier, Sanofi Synthelabo, Glaxo Smith Kline, Myriad, Lilly, Targacept, Novartis, Nestle, Merck Serono, Astra Zeneca, Neuropharma.

(h) Other service to the community

1. July, 20, 2012: Café Scientifique Alzheimer’s disease and brain health; Vancouver Public Library 2. May 18, 2012: Global Health and the Arts: A Forum on Mental Illness – Longwharf Theatre New Haven 3. May20, 2012: Canadian Neuroscience Society Public Forum, Boosting Brain Power May 20, 2012 – UBC 4. Jan 29, 2010: Global Health and the Arts: A Forum on Alzheimer’s Disease – Longwharf Theatre New Haven

CT, USA 5. Oct 2, 2008: Alzheimer Public Forum – Vancouver, BC 6. Sep 29, 2008: Interview with CTV Rhonda Low Show 7. July 17, 2008: Interview with Good Times Magazine 8. May 7, 2008: Interview with CBC Radio 9. March 10, 2008: Managing Forgetfulness Public Forum (Kelowna, BC) 10. February 4, 2008: Interview with the Health Report, ABC Radio National (Sydney, Australia) 11. January 21, 2008: Interview with the Canadian Health Magazine 12. November 29 & December 8, 2007: Interview with Dr. Art Hister, CKNW Radio 13. October 23, 2007: Appearance on CBC’s Almanac Show 14. October 22, 2007: Interview with The New Pharmacist Magazine 15. September 18, 2007: Interview with CBC FR Radio 16. August 10, 200:7 Interview with Matt Hartley, Globe and Mail 17. July 31, 2007: Interview with Canadian Living Magazine 18. July 19, 2007: Interview with The Medical Post 19. March 12, 2007: Managing Forgetfulness & Aging Successfully Public Forum, Barber Learning Center 20. January 12 & 15, 2007; Interview with CBC National News 21. January - March 2007: Knowledge Network Documentary: “Beyond Memory” 22. September 21, 2006: Mission for Memories Public Forum on Alzheimer's Disease with Dr. Roberta Bondar 23. May 13, 2006: UBC Alzheimer Clinic Research Forum 24. January 11, 2006: Interview with Dr. Art Hister, “House Calls” Radio Call in Show 25. July 8, 2005: Fanny Keifer Television Show, Cable 4 26. March 23, 2005: Opening of ALS Centre, GF Strong 27. January 29, 2005: Interview with Dr Art Hister, “House Calls” Radio Call in Show 28. January 28, 2005: Fannie Kiefer Show, Cable 4 29. November 18, 2004: Participation in NOW TV’s live call in show 30. January 21, 2004: Appearance on Bill Good Radio Show, CKNW Radio 31. January 19, 2004: Appearance on CBC’s Almanac Show with Mark Forsythe 32. January 07, 2004: Appearance on CBC, Yukon Call in Show 33. March 10, 2003: Research Awareness Week at UBC 34. January 21, 2003: Appearance on the Vicky Gabareau Television Show 35. October 9, 2002: Public Forum on Successful Brain Aging 36. January 19, 2002: “House Calls” Community Service Call-in radio show with Dr. Art Hister 37. February 10, 2001: CFUN Radio Alzheimer Disease Special Presentation 38. October 8, 2000: Interview with Dr. Art Hister, “House Calls” Radio Call in Show 39. May 2000: Alzheimer Society of B.C. Provincial Conference

29

40. December 1999: Alzheimer Public Forum – Vancouver, BC 41. January 1999: Alzheimer Public Forum – Vancouver, BC 42. April 1998: Oakridge Seniors Centre 43. May 1994: M.O.A.A. Vancouver Chapter 44. January 1994: UBC Alzheimer Clinical Research Day 45. September 1991: Boundary Health Unit 46. May 1990: Richmond Hospital Foundation 47. April 1988: ALS Society Meeting

11. AWARDS AND DISTINCTIONS (a) Awards for Teaching (indicate name of award, awarding organizations, date)

1. Nominee for Fay Dirks Teaching Award UBC Department of Medicine 1995 2. Prize for Best Rounds of the Year: Vancouver Hospital & Health Sciences Centre - Family Practice Grand

Rounds November 1994 Topic: New Developments in Therapy for Alzheimer Disease

(b) Awards for Scholarship (indicate name of award, awarding organizations, date)

1. Vancouver Hospital Brain Research Center: Clinical Investigator Award 1999 - 2000 2. Vancouver Hospital: Neuroscience Investigator Award 1998 - 1999 3. Vancouver Hospital: Investigator Award 1997 - 1998 4. UBC Department of Medicine: Martin M. Hoffman Award for Excellence in Research 1997 5. McGill University Medical School: University Scholar 1978

(c) Other Awards and Distinctions

1. UBC Faculty of Medicine: Distinguished Achievement Award for Outstanding Contribution by a Senior Faculty Member 2008

2. Elected Fellow of the Canadian Academy of Health Sciences 2008 - Present 3. Ralph Fisher and Alzheimer Society of BC Endowed Professorship in Alzheimer’s Research 2007 - Present 4. Best Doctors (Canada) 2005 - 2006; 2007 - 2008 5. Profile in Lancet Neurology: Howard Feldman “Master of Dementia” 2007; 6 (6) 482 6. Vancouver Acute Medical Staff Award: For Bringing Clinical Renown to Vancouver Acute 2007 7. Vancouver Hospital Medical Staff: Academic Award for Scientific Achievement 2001

30

THE UNIVERSITY OF BRITISH COLUMBIA Publications Record

Updated: March 27, 2013

SURNAME: FELDMAN FIRST NAME: HOWARD

REFEREED PUBLICATIONS (a) Journals

1. Jacova C, Hsiung GY R, Tawakanjanachot I, Dinelle K, McCormick S, Gonzalez M, Lee H, Sengdy P, Bouchard-

Kerr P, Baker M, Rademakers R, Sossi V, Stoessl AJ, Feldman HH and Mackenzie IRA Regional Anterior Cerebral Glucose Hypometabolism on (18) F-FDG PET is a Predementia Signature in GRN mutation Carriers. Neurology 2013 in press

2. Peters KR, Beattie BL, Feldman HH, Illes J; A Conceptual Framework and Ethics Analysis for Prevention Trials in Alzheimer’s Disease Progress in Neurobiology ; Manuscript in press

3. Carrillo MC, Brashear HR, Logovinsky V, Ryan JM, Feldman HH, Siemers ER, Abushakra S, Hartley DM, Petersen RC, Khachaturian AS, Sperling RA; Can We Prevent Alzheimer’s Disease? Secondary Prevention Trials in Alzheimer’s Disease; Alzheimer’s and Dementia; Manuscript in press

4. Chertkow H, Feldman HH, Jacova C, Massoud F; Review: Definitions of Dementia and Predementia States in Alzheimer’s disease and Vascular Cognitive Impairment: Consensus from the Canadian Conference on the Diagnosis of Dementia; Alzheimer’s Research and Therapy; Manuscript in press MS 1852715877869818

5. Albright C, Dockens R, Meredith JE, Olson RE, Slemmon R, Lentz KA, Wang JS, Denton RR, Pilcher G, Rhyne PW, Raybon JJ Barten DM. Burton C, Toyn JH, Sankaranarayanan S, Polson C, Guss V, White R, Simutis F, Sanderson T, Gillman KG, Starrett J, Bronson J, Sverdlov O, Huang SP, Castaneda L, Feldman HH, Coric V, Zaczek R, Macor JE, Houston J, Berman RM and Tong G Pharmacodynamic of Selective Inhibition of Gamma Secretase by Avagacestat Journal Pharmacology and Experimental Therapeutics Manuscript 199356 in press

6. Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Pilcher G, Colby S, Rollin L, Dockens R, Pachai C, Portelius E, Andreasson U, Blennow K, Soares H, Albright C, Feldman HH, Berman RM. Safety and Tolerability of the Gamma Secretase Avagacestat in a Phase 2 Study of Mild-to-Moderate Alzheimer’s disease. Arch Neurol 2012 Aug 13 1-12 Epub ahead of print [PMID 22892585]

7. Boxer AL, Gold M, Huey E, Hu W, Rosen H, Kramer J, Gao FB, Burton E, Chow T, Kao A, Leavitt B, Lamb B, Grether M, Knopman D, Cairns N, Mackenzie I, Mitic L, Roberson ED, Kammen DV, Cantillon M, Zahs K, Jackson G, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian S, Sutherland M, Abushukra S, Seubert P, Lewcock J, Farese R, Kenet R, Laferla F, Perrin S, Whittaker S, Honig L, Boeve B, Grossman M, Miller B, Cummings J. Molecules and animal models for FTD drug development (Part 1 of FTD: the Next Therapeutic Frontier) Alz and Dementia 2012 Oct 9 Epub ahead of print [PMID 23062850]

8. Boxer AL, Gold M, Huey E, Hu W, Rosen H, Kramer J, Gao FB, Burton E, Chow T, Kao A, Leavitt B, Lamb B, Grether M, Knopman D, Cairns N, Mackenzie I, Mitic L, Roberson ED, Kammen DV, Cantillon M, Zahs K, Jackson G, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian S, Sutherland M, Abushukra S, Seubert P, Lewcock J, Farese R, Kenet R, Laferla F, Perrin S, Whittaker S, Honig L, Boeve B, Grossman M, Miller B, Cummings J. The Advantages of FTD Drug Development (Part 2 of FTD: the Next Therapeutic Frontier) Alz and Dementia 2012 Oct 9 Epub ahead of print [PMID 23043900]

9. Hsiung GY, Dejesus-Hernandez M, Feldman HH, Sengdy P, Bouchard-Kerr P, Dwosh E, Butler R, Leung B, Fok A,

Rutherford NJ, Baker M, Rademakers R, and Mackenzie IR Clinical and Pathological Features of Familial

31

Frontotemporal Dementia caused by C9ORF72 Mutation on Chromosome 9p. Brain 2012 Mar; 135 (3) 709-22 and Feb 17, 2012 epub ahead of print [PMID 22344582]

10. Petkau TL, Neal SJ, Milnerwood A, Mew A, Orban P, Gregg J, Lu G, Feldman HH, Mackenzie IR, Raymond LA, Leavitt BR Synaptic Dysfunction in Progranulin-Deficient Mice Neurobiol Dis. 2012 Feb: 45 (2) 711-22 and Oct 25, 2011 epub ahead of print [PMID 22062772]

11. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch AN.

Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung GYR, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek AK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson SD, Boylan K, Graff Radford NR and Rademakers R Expanded GGGGCC Hexanucleotide Repeat in Non-Coding Region of C9ORF72 Causes Chromosome 9p-Linked Frontotemporal Dementia and Amyotrophic Lateral Sclerosis Neuron 2011 Oct 20; 72 (2) 245-56, Sept 21 2011 [PMID 21944778]

12. Vellas B, Aisen PS, Samaio C, Carrillo M, Scheltens P, Scherrer B, Frisoni GB, Weiner M, Schneider L, Gauthier S, Gispen-de Wied CC, Hendrix S, Feldman H, Cedarbaum J, Petersen R, Siemers E, Andrieu S, Prvulovic D, Touchon J, Hampel Prevention Trials in Alzheimer Disease: An EU-US Task Force Report Prog Neurobiol. 2011 Dec: 95 (4) 594-600 and Sep 10, 2011 epub ahead of print [PMID 21925234]

13. Sperling R*, Jack C*, Black S, Frosch M, Greenberg SM, Hyman B, Scheltens P, Carrillo M, Thies W, Bednar M, Black R, Brashear R, Grundman M, Siemers E, Feldman HH* and Schindler M* Recommendations from the Alzheimer Association Roundtable Workgroup on Amyloid Related Imaging Abnormalities in Amyloid Modifying Therapeutic Trials. Alzheimer’s and Dementia 2011 Jul: 7 (4) 367-85 PMID 21784348 * equal contribution as lead authors [PMID 21784348]

14. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ,

Petersen RC, Snyder PJ, Carrillo M, Thies B, Phelps CH The Diagnosis of Mild Cognitive Impairment Due to Alzheimer’s Disease: Recommendations from the National Institute of Aging and Alzheimer Association Workgroup. Alzheimer’s & Dementia 2011 May:7 (3) 270-279 and April 21, 2011 epub ahead of print [PMID 21514249].

15. Doody RS, Cole PE, Miller DS, Siemers ES, Black R, Feldman H, Schindler R, Graham S, Heath T,

Khachaturian A, Evans R, Carrillo MC Global Issues in Drug Development for AD Alzheimer’s and Dementia 2011 Mar 7; (2) 197-207 [PMID 21414556].

16. Chen Plotkin AS, Martinez-Lage M Sleiman PMA, Hu W, Greene R. McCarty Wood E, Bing S, Grossman M, Schellenberg G, Hatanpaa K, Weiner MF, White CL, Brooks W, Halliday GM, Krill JJ, Gearing M, Beach TG, Graff Radford NR, Dickson DW, Rademakers R, Boeve BF, Pickering Brown SM, Snowden J, van Swieten JC, Seelaar H, Murrell JR, Ghetti B, Spina S, Grafman J, Kaye JA, Woltjer RL, Mesulam M, Llado A, Miller BL, Alzualde A, Moreno F, Rohrer JD, Mackenzie IRA, Feldman HH, Hamilton RL, Cruts M, Engleborghs S, De Deyn PP, Van Broeckhoven, Bird TD, Cairns NJ, Goate A, Frosche MP, Riederer PF, Bogdanovic N, Lee VMY, Trojanowski JQ, Van Deerlin VM Genetic and Clinical Features of Progranulin Associated Frontotemporal Lobar Degeneration Arch Neurol 2011 April; 68 (4) 488-97 [PMID 21482928].

17. Hsiung G-YR, Fok A, Feldman HH, Rademakers R and Mackenzie IRA. Rs5848 Polymorphism and Serum Progranulin Level J Neurological Sciences 2011 Jan 15: 300 (1-2) 28-32 Epub 2010 Nov 2 [PMID 21047645]

18. Dubois B*, Feldman HH*, Jacova C, Cummings J, DeKosky ST, Barberger Gateau P. Delacourte A, Frisoni G, Fox

NC, Galasko D, Gauthier S. Hampel H. Jicha GA, Meguro K, O’Brien J, Pasquier , Robert P, Rossor M, Salloway S, Sarazin M, deSouza LC, Stern Y. Visser PJ and Scheltens P. Revising the Definition of Alzheimer’s Disease: A new lexicon Lancet Neurology 2010 Nov; 9(11) 118-27;Epub 2010 Oct 9, [PMID 20934914] (* co first authored)

Correspondence on # 7 Feldman HH, Scheltens PS and Dubois B for the International Working Group on New Research Criteria for Alzheimer’s Disease Response to Letters to the Editor Lancet Neurology 2011 April 10; (4) 300-301 PMID 21435595

32

19. Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, Feldman H, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, Potter WZ, Thomas RG, Salmon D, Donohue M, Bednar M, Touchon J, Vellas B. Report of the Task Force on Designing Clinical Trials in Early (Pre-Dementia) AD. Neurology 2011 Jan 18; 76 (3) 280-286 epub ahead of print 2010 Dec 22 [PMID 21178097].

20. Boxer AL, Mackenzie IRA, Boeve BF, Baker M, Seeley WW, Crook R, Feldman HH, Hsiung GYR, Rutherford N, Laluz V, Whitwell J, Foti D, McDade E, Molano J, Karydas A, Wojtas A, Goldman J, Mirksy J, Sengdy P, DeArmond S, Miller BL and Rademakers R Clinical, Neuroimaging and Neuropathological Variability in a New Chromosome 9P-Linked FTD-ALS Family. Journal of Neurology, Neurosurgery and Psychiatry 2011; Feb; 82 (2):196-203 Epub ahead of print 2010 June 20 [ PMID 20562461]

21. Fenghua H, Padukkavidana T, Vaegter C, Brady O, Zheng Y, MacKenzie I, Feldman H, Nykjaer A, Strittmatter SM.

Sortilin-Mediated Endocytosis Determines Levels of the Fronto-Temporal Dementia Protein, Progranulin. Neuron 2010 Nov 18; 68(4) 654-67 [PMID 21092856]

22. Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, Wu X, Gentile KA, Huang SP, Emison E,

Delmonte T, D’Souza BB, Zimbroff DL, Grebb JA, Goddard AW, Stock EW Depression Anxiety 2010 May; 27, (5) 417-425 [PMID 20455246]

23. Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR, Feldman HH, Bokde AWL, Alexander GE,

Scheltens P, Vellas B, Dubois B, Weiner M and Hampel H in Colloboration with the North American ADNI Neurobiology of Aging 2010 Dec 13 Epub ahead of print [PMID 21159408]

24. Petkau TL, Neal SJ, Orban PC, MacDonald JL, Hill AM, Lu G, Feldman HH, Mackenzie IR and Leavitt BR

Progranulin expression in the developing and adult murine brain. J Comp Neurol 2010 Oct 1, 518 (19):3931-47 [PMID 20737593]

25. Olazaran J, Reisberg B, Clare L, Cruz I, Pena-Casanova J, del Ser T, Woods B, Beck C, Auer S, Lai C, Spector A,

Fazio S, Bond J, Kivipelto M, Brodaty H, Rojo JM, Collins H, Teri L, Mittelman M, Orrell M, Feldman HH, and Muniz R. Non Pharmacological Therapies in Alzheimer’s Disease: A Systematic Review of Efficacy Dementia and Geriatric Cognitive Disorders 2010; 30; 161-178 [PMID 20838046]

26. Butler R, Beattie BL. Thong UP, Dwosh E. Guimond C, Feldman HH, Hsiung GY, Rogaeva E, St George Hyslop P,

Sadovnick AD A Novel PS 1 gene mutation in a large Aboriginal kindred; Can J Neurol Sci 2010 May; (37) 302-3 [PMID 20481270]

27. McLaughlin T, Feldman H, Fillit H, Sano M, Schmitt F, Aisen P, Leibman C, Mucha L, Ryan JM, Sullivan SD,

Spackman E, Neumann P, Cohen J, and Stern Y. “Dependence” as a unifying construct in defining Alzheimer disease severity. Alzheimer’s & Dementia 2010 Nov 6 (6) 482-93 [PMID 21047645].

28. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi JH,

DeMicco DA, and Breazna A. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010 March 23; 74 (12):956-64 Epub ahead of print March 3, 2010; [PMID 20200346].

29. Van Deerlin VM, Sleiman PMA, Martinez-Lage M, Chen-Plotkin A, Wang L-S, Graff-Radford NR, Dickson DW, Rademakers R, Boeve BF, Grossman M, Arnold SE, Mann DMA, Pickering-Brown SM, Seelaar H, Heutink P, van Swieten JC, Murrell JR, Ghetti B, Spina S, Grafman J, Hodges J, Spillantini MG, Sid G, Lieberman AP, Kaye JA, Woltjer RL, Bigio EH, Mesulam M, al-Sarraj S, Troakes C, Rosenberg RN, White CL III, Ferrer I, Lladó A, Neumann M, Kretzchmar HA, Hulette CM, Welsh-Bohmer KA, Miller BL, Alzualde A, de Munain AL, McKee AC, Gearing M, Levey AI, Lah JJ, Hardy J, Rohrer JD, Lashley T, Mackenzie IRA, Feldman HH, Hamilton RL, Dekosky ST, van der Zee J, Kumar-Singh S, Van Broeckhoven CV, Mayeux R, Vonsattel JPG, Troncoso JC, Kril JJ, Kwok JBJ, Halliday GM, Bird TD, Ince PG, Shaw PJ, Cairns NJ, Morris JC, McLean CA, DeCarli C, Ellis WG, Freeman SM, Frosch MP, Growdon JH, Perl DP, Sano M, Bennett DA, Schneider JA, Beach TG, Reiman EM, Woodruff BK, Cummings J, Vinters HV, Miller CA, Chui HC, Alafuzoff I, Hartikainen P, Seilhean D, Galasko D, Masliah E, Cotman CW, Tuñón MT, Martínez MCC, Munoz DG, Carroll SL, Marson D, Riederer PF, Bogdanovic N, Schellenberg GD, Hakonarson

33

H, Trojanowski JQ and Lee VM-Y. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nature Genetics 2010 Mar; 42 (3):234-9, [Epub ahead of print February 14, 2010, PMID 20142524].

30. Yu C-E, Bird TD, Bekris LM, Leverenz JB, Steinbart E, Galloway NM, Feldman H, Woltger R, Miller CA, Wood EM, Grossman M, McCluskey L, Clark CM, Neumann M, Danek A, Galasko DR, Arnold S, Chen-Plotkin A, Karydas A, Miller BL, Trojanowski JQ, Lee VMY, Schellenberg GD, and Van Deerlin VM. The Spectrum of Mutations in Progranulin: A Collaborative Study Screening 545 Cases of Neurodegeneration. Archives of Neurology 2010; 67(2): 161-170 [PMID 20142524].

31. Davidson JE, Irizarry MC, Bray BC, Wetten S, Galwey N, Gibson R, Borrie M, Delisle R, Feldman HH, Hsiung G-Y, Fornazzari L, Gauthier S, Guzman D, Loy-English I, Keren R, Kertesz A, St. George-Hyslop P, Wherrett J, and Monsch AU. An exploration of cognitive subgroups in Alzheimer’s Disease. Journal of the International Neuropsychological Society 2010; 16(2): 233-243 [PMID 19958568].

32. Moorhouse P, Song X, Rockwood K, Black S, Kertesz A, Gauthier S, and Feldman H, on behalf of the Consortium to Investigate Vascular Impairment of Cognition. Executive dysfunction in vascular cognitive impairment in the consortium to investigate vascular impairment of cognition study. Journal of the Neurological Sciences 2010; 288(1-2): 142-146 [PMID 19840883].

33. Woodward M, Black S, Jacova C, Kertesz A, Mackenzie IR, Feldman HH and the ACCORD Investigator Group. Differentiating the frontal variant of Alzheimer’s Disease. International Journal of Geriatric Psychiatry 2010 Jul 25 (7) 732-8 [Epub ahead of print October 12, 2009 PMID 19823987].

34. Jones RW, Schwam E, Wilkinson D, Waldemar G, Feldman HH, Zhang R, Albert K, and Schindler R. Rates of

Cognitive Change in Alzheimer’s Disease: Observations Across a Decade of Placebo Controlled Clinical Trials With Donepezil. Alzheimer’s Disease & Associated Disorders 2009; 23(4): 357-364.

35. Wilkinson D, Schindler R, Schwam E, Waldemar G, Jones R, Gauthier S, Lopez OL, Cummings J, Xu Y, and

Feldman HH. Effectiveness of Donepezil in Reducing Clinical Worsening in Patients with Mild-to-Moderate Alzheimer’s Disease. Dementia & Geriatric Cognitive Disorders 2009; 28(3): 244-251.

36. Lanctot KL, Hsiung G-YR, Feldman HH, Masoud ST, Sham L, and Herrmann N. Assessing the validity of deriving

Clinical Dementia Rating (CDR) Global scores from independently-obtained Functional Rating Scale (FRS) scores in vascular dementia with and without Alzheimer’s disease. International Journal of Geriatric Psychiatry 2009; 24(10):1174-1176.

37. Ferris S, Lane R, Sfikas N, Winblad B, Farlow M, and Feldman HH. Effects of gender on response to treatment

with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach. Gender Medicine 2009; 6(2): 345-355.

38. Kandiah N and Feldman HH. Therapeutic potential of statins in Alzheimer’s disease. Journal of the Neurological

Sciences 2009; 283(1-2): 230-234.

39. Brooks BL, Iverson GL, Feldman HH, and Holdnack JA. Minimizing misdiagnosis: Psychometric criteria for possible or probable memory impairment. Dementia & Geriatric Cognitive Disorders 2009; 27(5): 439-450.

40. Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Schwalen S, and Kavanagh S. Treatment with

galantamine and time to nursing home admission in Alzheimer disease patients with and without cerebrovascular disease. International Journal of Geriatric Psychiatry 2009; 24(5): 479-488.

41. Feldman HH and Jacova C. Predicting treatment response to acetylcholinesterase inhibitor treatment in Alzheimer

disease: has the time come? Nature Clinical Practice Neurology 2009; 5(3):128-129.

34

42. Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Brashear HR, Berlin J, Battisti W and Kavanagh S. Analyses of mortality risk in dementia patients treated with galantamine. Acta Neurologica Scandinavica 2009; 119(1): 22-31.

43. Rademakers R, Eriksen JL, Baker M, Robinson T, Ahmed Z, Lincoln SJ, Finch N, Rutherford NJ, Crook RJ,

Josephs KA, Boeve BF, Knopman DS, Petersen RC, Parisi JE, Caselli RJ, Wszolek ZK, Uitti RJ, Feldman HH, Hutton ML, Mackenzie IR, Graff-Radford NR and Dickson DW. Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Human Molecular Genetics 2008; 17(23): 3631-3642.

44. Feldman HH, Maia LF, Mackenzie IRA, Forster BB, Martzke J, and Woolfenden A. Superficial siderosis: A

diagnostic marker of Cerebral Amyloid Angiopathy in Alzheimer’s Disease. Stroke 2008; 39(10): 2894-2897 [PMID 18635858].

45. Hsiung G-YR and Feldman HH. Pharmacological treatment in moderate-to-severe Alzheimer’s disease. Expert

Opinion on Pharmacotherapy 2008 Oct.; 9(15): 2575-2582. 46. Gauthier S, Dubois B, Feldman HH, and Scheltens P. Revised research criteria for Alzheimer’s disease. Lancet

Neurology 2008; 7(8): 668-670. 47. Winblad B, Gauthier S, Scinto L, Feldman HH, Wilcock GK, Truyen L, Wang D, Nye JS, Brashear HR, and the

GAL-INT-11/18 Study Group. Safety and Efficacy of Galantamine in Subjects with Mild Cognitive Impairment. Neurology 2008; 70(22): 2024-2035.

48. Feldman HH and Kandiah N. The Early Identification of AD: What have we learned from MCI? CNS Spectrums

2008; 13 (3 Suppl. 3): 4-7. 49. Jones RW, Kivipelto M, Feldman HH, Sparks L, Doody R, Waters D, Hey-Hadavi J, Breazna A, Schindler RJ, and

Ramos H, on behalf of the LEADe Investigators. The Atorvastatin/Donepezil in Alzheimer’s Disease Study (LEADe): Design and Baseline Characteristics. Alzheimer’s & Dementia 2008; 4(2): 145-153.

50. Brooks BL, Iverson GL, Holdnack JA, and Feldman HH. The potential for misclassification of Mild Cognitive

Impairment: A study of memory scores on the Wechsler Memory Scale-III in Healthy Older Adults. Journal of the International Neuropsychological Society 2008; 14(3): 463-478.

51. Hsiung G-YR, Alipour S, Jacova C, Grand J, Gauthier S, Black SE, Bouchard RW, Kertesz A, Loy-English I, Hogan

DB, Rockwood K, and Feldman HH. Transitions from CIND to Alzheimer’s Disease: An analysis of changes in functional abilities. Dementia & Geriatric Cognitive Disorders 2008; 25(6): 483-490.

52. Feldman HH, Jacova C, Robillard A, Garcia A, Chow T, Borrie M, Schipper HM, Blair M, Kertesz A, and Chertkow

H. The Diagnosis and Treatment of Dementia. Canadian Medical Association Journal 2008; 178(7): 825-836. 53. Lane R, Feldman HH, Meyer J, He Y, Ferris SH, Nordberg A, Darreh-Shori T, Soininen H, Pirttilä T, Farlow MR,

Sfikas N, Ballard C, and Greig NH. Synergistic effect of apolipoprotein E ε4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer’s disease. Pharmacogenetics & Genomics 2008; 18: 289-298.

54. Jacova C, Peters KR, Wong E, Beattie BL, Foti D, Scheltens P, Li DKB, and Feldman HH. Cognitive Impairment No

Impairment (CIND) – Neuropsychological and Neuroimaging Characterization of an Amnestic Subgroup. Dementia & Geriatric Cognitive Disorders 2008; 25(3): 238-247.

55. Li H, Wetten S, L, St Jean PL, Upmanyu R, Surh L, Hosford D, Barnes M, Briley JD, Borrie M, Coletta N, Delisle R,

Dhalla D, Ehm MG, Feldman HH, Fornazzari L, Gauthier S, Goodgame N, Guzman D, Hammond S, Hollingworth

35

P, Hsiung G-YR, Johnson J, Kelly DD, Keren R, Kertesz A, King KS, Lovestone S, Loy English I, Matthews, P. Owen MJ, Plumpton M, Pryce Phillips W, Prinjha R, Gibson RA, Irizarry MC, Middleton LT, and Roses AD. Candidate Single Nucleotide Polymorphisms from a Genome-Wide Association Study of Alzheimer’s Disease Archives of Neurology 2008; 65(1): 45-53.

56. Peters KR, Rockwood K, Black SE, Hogan DB, Gauthier SG, Loy-English I, Hsiung G-YR, Jacova C, Kertesz A, and

Feldman HH. Neuropsychiatric symptom clusters and functional disability in cognitively-impaired-not-demented individuals. American Journal of Geriatric Psychiatry 2008; 16(2): 136-144.

57. Hallam BJ, Silverberg ND, LaMarre AK, Mackenzie IRA, and Feldman HH. Clinical presentation of prodromal

frontotemporal dementia. American Journal of Alzheimer’s Disease & Other Dementias 2007; 22(6): 456-467. 58. Jacova C, Kertesz A, Blair M, Fisk J, and Feldman HH. Neuropsychological testing and assessment for dementia.

Alzheimer’s & Dementia 2007; 3: 299-317. 59. Feldman H and Lane R. Rivastigmine three times daily improves cognition and response in Alzheimer’s disease.

Evidence-Based Mental Health 2007; 10(4): 116. 60. Hsiung G-YR, and Feldman HH (September 2007). GRN-Related Frontotemporal Dementia in: Pagon RA, Bird TC,

Dolan CR, Stephens K editors GeneReviews Internet at GeneTests: Medical Genetics Information Resource [database online]. Copyright, University of Washington, Seattle, 1997-2007. Available at http://www.genetests.org.

61. Rademakers R, Baker M, Gass J, Adamson J, Huey E, Momeni P, Spina S, Coppola G, Karydas A, Stewart H,

Johnson N, Hsiung G-YR, Kuntz K, Steinbart E, McCarty Wood E, Josephs K, Sorenson E, Womack K, Pickering-Brown SM, Lee VY, Schofield P, Ghetti B, Schellenberg GD, Beach TG, Mesulam M, Grafman J, Mackenzie I, Feldman HH, Bird T, Petersen R, Knopman D, Boeve B, Geschwind D, Miller B, Wzsolek Z, Lippa C, Bigio E, Dickson D, Graff-Radford N and Hutton M. An international initiative to study phenotypic variability associated with progranulin haploinsufficiency in patients with the common c.1477C>T (p.R493X) mutation. Lancet Neurology 2007; 6(10): 857-868.

62. Dubois B *, Feldman HH *, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jacova C,

Jicha G, Meguro K, Morris J, O’Brien J, Pasquier F, Robert P, Rossor M Salloway S, Stern Y, Visser PJ and Scheltens P. Research criteria for the diagnosis of Alzheimer’s disease: Revising of the NINCDS-ADRDA criteria. Lancet Neurology 2007; 6(8): 734-746. (* co-first authors) [2008 Amedeo Prize, 7th Place]

63. Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, Del Ser T, Inzitari

D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, and Lane R. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurology 2007 Jun.; 6(6): 501-512.

64. Rockwood K, Chertkow H, and Feldman HH. Mild Cognitive Impairment: Canadian Journal of Neurological

Sciences 2007; 34 (Suppl. 1): S90-S96. 65. Feldman HH and Jacova C. Primary Prevention and Delay of Onset of Alzheimer Disease and Dementia. Canadian

Journal of Neurological Sciences 2007; 34 (Suppl. 1): S84-S89. 66. Blair M, Kertesz, A, Davis-Faroque N, Hsiung G-YR, Black SE, Bouchard RW, Gauthier S, Guzman DA, Hogan DB,

Rockwood K, and Feldman H. Behavioural Measures in Frontotemporal Lobar Degeneration and Other Dementias: The utility of the frontal behavioural inventory and the neuropsychiatric inventory in a national cohort study. Dementia & Geriatric Cognitive Disorders 2007 Apr. 20; 23(6): 406-415.

67. Feldman HH and Lane R. Rivastigmine: A placebo-controlled trial of BID and TID regimens in patients with

Alzheimer's disease. Journal of Neurology, Neurosurgery, & Psychiatry 2007; 78(10): 1056-1063.

http://www.genetests.org/

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17509485&query_hl=3&itool=pubmed_docsum




36

68. Maia L, Mackenzie IRA, and Feldman HH. Clinical phenotypes of cerebral amyloid angiopathy. Journal of the

Neurological Sciences 2007; 257(1-2): 23-30. 69. Rockwood K, King Moorhouse P, Song X, Macknight C, Gauthier S, Kertesz A, Montgomery P, Black S, Hogan DB,

Guzman A, Bouchard R, and Feldman HH. Disease progression in vascular cognitive impairment: Cognitive, functional and behavioural outcomes in the Consortium to Investigate Vascular Impairment of Cognition (CIVIC) cohort study. Journal of the Neurological Sciences 2007; 252: 106-112.

70. Feldman HH, Schmitt FA, and Olin JT. Activities of Daily Living in Moderate to Severe Alzheimer’s Disease: An

analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Disease & Associated Disorders 2006; 20(4): 263-268.

71. Jacova C, Hsiung G-YR, and Feldman HH. Dropouts and Refusals in Observational Studies: Lessons for

Prevention Trials. Neurology 2006; 67 (9 Suppl. 3): S17-S20. 72. Mackenzie IRA, Baker M, Pickering-Brown S, Hsiung G-YR, Lindholm C, Dwosh E, Gass J, Cannon A, Hutton M,

and Feldman HH. The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain 2006; 129: 3081-3090.

73. Burns A, O'Brien J; BAP Dementia Consensus group; Auriacombe S, Ballard C, Broich K, Bullock R, Feldman H,

Ford G, Knapp M, McCaddon A, Iliffe S, Jacova C, Jones R, Lennon S, McKeith I, Orgogozo JM, Purandare N, Richardson M, Ritchie C, Thomas A, Warner J, Wilcock G, Wilkinson D; British Association for Psychopharmacology. Clinical practice with anti-dementia drugs: a consensus statement from the British Association for Psychopharmacology (BAP). Journal of Psychopharmacology 2006; 20(6): 732-755.

74. Neumann M, Sampathu DM, Kwong LK, Truax AC, Miscenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark

C, McKlusky L, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, and Lee VM-Y. TDP-43 is the major disease protein ubiquitinated in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314 (5796): 130-133.

75. Hsiung G-YR, Donald A, Grand J, Black SE, Bouchard RW, Gauthier SG, Loy-English I, Hogan DB, Kertesz A,

Rockwood K, and Feldman H. Outcomes of Cognitively Impaired Not Demented (CIND) at 2-years in the Canadian Cohort Study of Cognitive Impairment and Related Dementias (ACCORD). Dementia & Geriatric Cognitive Disorders 2006; 22(5-6): 413-420.

76. Gass J, Cannon A, Mackenzie IR, Boeve B, Baker M, Adamson J, Crook R, Melquist S, Kuntz K, Petersen R,

Josephs K, Graff-Radford N, Dickson D, Wsolek Z, Gonzales J, Beach T, Bigio E, Mesalum M, White C, Feldman H, Knopman D, Hutton M, and Rademakers R. Mutations in proganulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Human Molecular Genetics 2006; 15(20): 2988-3001.

77. Mackenzie IR, Butland SL, Devon RS, Dwosh E, Feldman H, Lindholm C, Neal SJ, Ouellette BF, and Leavitt BR.

Familial Frontotemporal Dementia with Neuronal Intranuclear Inclusions is not a Polyglutamine Expansion Disease. BMC Neurology 2006; 6: 32.

78. Baker M, Mackenzie IR, Pickering Brown SM, Gassi J, Rademaker R, Lindholm C, Snowden J, Adamson J,

Sadovnick AD, Rollinson S, Crut M, Cannon A, Dwosh E, Neary D, van der Zee J, Melquist S, Richardson A, Gijselincka I, Eriksen J, Robinson T, Zehr C, Dickey CA, McGowan E, Mann D, Boeve B, Feldman H, and Hutton M. Mutations in Progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006; 442 (7105): 916-919.

79. Grundman M, Petersen RC, Bennett D, Feldman H, Salloway S, Visser PJ, Thal LJ, Schenk D, Khachaturian Z,

and Thies W, for the Alzheimer’s Association Research Roundtable. Alzheimer Association Research Roundtable Meeting on Mild Cognitive Impairment: What have we learned? Alzheimer’s & Dementia 2006; 2(3): 220-233.





37

80. Gauthier S, Reisberg B, Zaudig M, Peterson R, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H,

Cummings JL, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney M, Whitehouse P, and Winblad B, on behalf of the participants of the IPA Conference on MCI. Mild Cognitive Impairment. Lancet 2006; 367:1262-1270.

81. Feldman H, Gauthier S, Chertkow H, Conn DK, Freedman M, and MacKnight C on behalf of the 2nd Canadian

Conference on Antidementia Guidelines Committee. Canadian Guidelines for the Development of Antidementia Therapies: a conceptual summary. Canadian Journal of Neurological Sciences 2006; 33(1): 1-26.

82. Peters KR, Rockwood K, Gauthier S, Kertesz A, Sadovnick D, Beattie L, and Feldman H. Characterizing

Neuropsychiatric Symptoms Across the Spectrum of Cognitive Impairment. Neurology 2006; 66: 523-529. 83. Alagiakrishnan K, McCracken P, and Feldman H. Treating vascular risk factors and maintaining vascular health: Is

this the way towards successful cognitive ageing and preventing cognitive decline? Postgraduate Medical Journal 2006; 82(964): 101-105.

84. Mackenzie IR, Baker M, Adamson J, Qadi N, Feldman H, Lindholm C, Melquist S, Sadovnick D, Dwosh E, Hutton

M, and Pickering-Brown SM. Familial Tau-Negative Frontotemporal Dementia with Neuronal Intranuclear Inclusions is Linked to Chromosome 17. Brain 2006; 129(4): 853-867.

85. Rockwood K, Song X, Hogan DB, Black SE, Gauthier S, MacKnight C, Vandorpe R, Guzman A, Montgomery P,

Kertesz A, Bouchard RM, and Feldman H. Clinical and radiographic subtypes of Vascular Cognitive Impairment in a clinical-based cohort study. Journal of the Neurological Sciences 2006; 240(1-2): 7-14.

86. Shobab L, Hsiung G-YR, and Feldman H. The Role of Cholesterol in the Pathogenesis of Alzheimer’s Disease.

Lancet Neurology 2005; 4(12): 841-852. 87. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda J, Lippa C, Perry EK,

Aarsland D, Arai H, Ballard CH, Boeve B, Burn DJ, Costa D, Del Ser T, Bubois B, Galasko D, Gauthier S, Goetz C, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria R, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee V, Lees A, Litvan I, Londos E, Lopez O, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska E, Pasquier F, Perry RH, Schulz J, Trojanowski J, and Yamada M, for the Consortium on DLB. Dementia with Lewy Bodies: Diagnosis and Management: Third Report of the DLB Consortium. Neurology 2005; 65(12): 1863-1872.

88. Feldman H and Woodward M. The Staging and Assessment of Moderate to Severe Alzheimer’s Disease Neurology

2005; 65(6): S3: S10-S17. 89. Mackenzie IRA and Feldman H. Ubiquitin Immunohistochemistry in Classical MND, MND with Dementia and FTD-

MND Type. Journal of Neuropathology & Experimental Neurology 2005; 64(8): 730-739. 90. Feldman H and Jacova C. Mild Cognitive Impairment. American Journal of Geriatric Psychiatry 2005; 13(8): 645-

655. (invited peer review article) 91. Feldman H, Gauthier SG, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM and the Donepezil MSAD Study

Investigators Group. Efficacy and Safety of Donepezil in Patients with Severe Alzheimer's Disease: evidence from a randomized, placebo-controlled trial. International Journal of Geriatric Psychiatry 2005; 20: 559-569.

92. Feldman H and Jacova C: Assessing Mental Status in Dementia: The Behavioral Neurology Assessment.

Canadian Journal of Neurological Sciences 2005; 32(2): 138-139. (invited editorial) 93. Peters KR, Graf P, Hayden S, and Feldman H. Neuropsychological Subgroups of Cognitively-Impaired-Not-

Demented (CIND) Individuals: Delineation, Reliability and Predictive Validity. Journal of Clinical & Experimental Neuropsychology 2005; 27:164-188.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16461472&query_hl=18&itool=pubmed_docsum

38

94. Feldman H, Hux M, and Schwam EM. Economic evaluation of donepezil in moderate to severe Alzheimer disease.

Neurology 2005; 64(7):1320. (Correspondence - Author Reply) 95. Feldman H, Van Baelen V, Kavanagh SM, and Torfs K. Cognition, function and caregiving time patterns in patients

with mild-to-moderate Alzheimer disease: a 12-month analysis. Alzheimer Disease & Associated Disorders 2005; 19(1): 29-36.

96. Peters KR, Graf P, Hayden S, and Feldman H. Neuropsychological Characterization of Cognitively-Impaired-Not-

Demented (CIND) Individuals: Clinical Comparison Data. Clinical Neuropsychologist 2004; 18(2): 208-228. 97. Hsiung G-YR, Sadovnick AD, and Feldman, H. Apolipoprotein E genotype as a risk factor for cognitive decline and

dementia: data from the Canadian Study on Health and Aging (CSHA). Canadian Medical Association Journal 2004 Oct. 12; 171(8): 863-867.

98. Feldman H, Gauthier SG, Hecker J, Vellas B, Hux M, Xu Y, Schwam E, Shah S and Mastey V. An Economic

Evaluation of Donepezil in Moderate to Severe AD. Neurology 2004 Aug. 24; 63(4): 644-650. 99. Mackenzie IRA and Feldman H. Neurofilament inclusion body disease with early onset frontotemporal dementia

and primary lateral sclerosis. Clinical Neuropathology 2004 Jul.-Aug.; 23(4): 183-193. 100. Voisin T, Reynish E, Portet F, Feldman H, and Vellas B. What are the treatment options for patients with severe

Alzheimer’s disease? CNS Drugs 2004; 18(9): 575-583. 101. Mackenzie IRA and Feldman H. Neuronal intranuclear inclusions distinguish familial FTD-MND type from sporadic

cases. Dementia & Geriatric Cognitive Disorders 2004; 17(4): 333-336. 102. Tabet N and Feldman H. Naproxen for treatment of Alzheimer's Disease. Cochrane Database of Systematic

Reviews (3) 2004. 103. Feldman H, Scheltens P, Scarpini E, Herrmann N, Mesenbrink P, Mancione L, Tekin S, Lane R, and Ferris S.

Behavioral symptoms in mild cognitive impairment: Findings from the InDDEx Study. Neurology 2004 Apr. 13; 62(7): 1199-1201.

104. Erkinjuntti T, Roman G, Gauthier S, Feldman H, and Rockwood K. Emerging Therapies for Vascular Dementia and

Vascular Cognitive Impairment. Stroke 2004 Apr.; 35(4): 1010-1017. 105. Mackenzie IRA and Feldman H. Extrapyramidal features in patients with motor neuron disease and dementia; a

clinicopathological correlative study. Acta Neuropathologica 2004 Apr.; 107(4): 336-340. 106. Spacey SD, Green GJ, Pastore M, McGillivray B, Fleming J, Gambetti P, and Feldman H. Fatal Familial Insomnia:

The First Account in a Family of Chinese Descent. Archives of Neurology 2004 Jan.; 61(1): 122-125. 107. McKeith IM, Mintzer J., Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda J, Feldman H,

Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez O, Machado J, O’Brien J, Playfer J, and Reid W. Dementia with Lewy Bodies. Lancet Neurology 2004 Jan.; 3(1): 19-28.

108. Scarpini ES, Scheltens P, and Feldman H. Treatment of Alzheimer's disease: Current status and new perspectives.

Lancet Neurology 2003; 2(9): 539-547. 109. Rockwood K, Davis H, MacKnight C, Vandorpe R, Gauthier S, Guzman A, Montgomery P, Black S, Hogan DB,

Kertesz A, Bouchard R, and Feldman H. The Consortium to Investigate Vascular Impairment of Cognition:

39

Background, methods and impact of diagnostic criteria on the study of vascular cognitive impairment. Canadian Journal of Neurological Sciences 2003; 30(3): 237-243.

110. Bird T, Knopman D, VanSwieten J, Rosso S, Feldman H, Tanabe H, Graff-Raford N, Geschwind D, Verpillat P, and

Hutton M. Epidemiology and genetics of frontotemporal dementia/Pick’s disease. Annals of Neurology 2003; 54(S5): S29-S31.

111. Tabet N and Feldman H. Ibuprofen for Alzheimer’s disease patients. In: Cochrane Library Systematic Reviews,

Issue 2, 2003. Oxford. 112. Mackenzie IRA and Feldman H. Neuronal intranuclear inclusions distinguish familial FTD-MND type from sporadic

cases. Acta Neuropathologica 2003; 105(6): 543-548. 113. Feldman H, Levy AR, Hsiung G-YR, Peters KR, Rockwood K, Black S, Bouchard RW, Gauthier SG, Guzman DA,

Hogan DB, Kertesz A, and Donald A; for the ACCORD Study Group. A Canadian Cohort Study of Cognitive Impairment and Related Dementias (ACCORD): Study methods and baseline results. Neuroepidemiology 2003; 22: 265-274.

114. Mackenzie IRA and Feldman H. The relationship between extramotor ubiquitin-immonreactive neuronal inclusions

and dementia in motor neuron disease. Acta Neuropathologica 2003; 105(2): 98-102. 115. Feldman H, Gauthier S, Hecker J, Vellas B, Emir B, Mastey V, Subbiah P, The Donepezil MSAD Study

Investigators Group. Efficacy of Donepezil on Maintenance of Activities of Daily Living in Patients with Moderate to Severe Alzheimer's Disease and the Effect on Caregiver Burden. Journal of the American Geriatrics Society 2003; 51(6): 737-744.

116. Feldman H. Treating Alzheimer’s Disease with Cholinesterase Inhibitors: What Have We Learned so Far? (invited

editorial) International Psychogeriatrics 2002; 14(1): 3–5. 117. Gauthier S, Feldman H, Hecker J. Vellas B, Subbiah P, Whalen E. Efficacy of Donepezil on Behavioral Symptoms

in Patients with Moderate to Severe Alzheimer’s Disease. International Psychogeriatrics 2002; 14: 389-404. 118. Gauthier S, Feldman H, Vellas B, Emir B, Subbiah P, The Donepezil MSAD Study Investigaters’ Group.

Functional, Cognitive and Behavioral Benefits of Donepezil in Patients With Moderate Alzheimer’s Disease. Current Medical Research & Opinion 2002; 18: 347-354.

119. Tabet N and Feldman H. Indomethacin for the treatment of Alzheimer’s disease patients. Cochrane Library

Systematic Reviews, Issue 2, 2002. Oxford. 120. Feldman H, Gabathuler R, Kennard M, Nurminen J, Levy D, Foti S, Foti D, Beattie BL, and Jefferies WA. Serum

p97 Levels as an Aid to Identifying Alzheimer’s Disease. Journal of Alzheimer’s Disease 2001; 3(5): 507-516. 121. Wentzel C, Rockwood K, MacKnight C, Hachinski V, Hogan DB, Feldman H, Ostbye T, Wolfson C, Gauthier S,

Verrault R, and McDowell I. Progression of Impairment in Patients with Vascular Cognitive Impairment Without Dementia. Neurology 2001; 57(4): 714-715.

122. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, and Whalen E. A 24-Week, Randomized, Double-Blind

Study of Donepezil in Moderate to Severe Alzheimer’s Disease. Neurology 2001; 57(2): 613-620. 123. Feldman H, Sauter A, Donald A, Gélinas I, Gauthier S, Torfs K, Parys W, and Mehnert A. The Disability

Assessment for Dementia Scale: A 12-Month Study of Functional Ability in Mild to Moderate Severity of Alzheimer’s Disease. Alzheimer Disease & Associated Disorders 2001; 15(2): 89-95.

40

124. Patterson C, Gauthier S, Bergman H, Cohen C, Feightner JW, Feldman H, Grek A, and Hogan DB. The

Recognition, Assessment and Management of Dementing Disorders. Canadian Journal of Neurological Sciences 2001; 28(Suppl.1): S3-S16.

125. Feldman H and Kertesz A. Diagnosis, Classification and Natural History of Degenerative Dementias. Canadian

Journal of Neurological Sciences 2001; 28(Suppl. 1): S17-S27. 126. Rockwood K, MacKnight C, Wentzel C, Black S, Bouchard R, Feldman H, Gauthier S, Hogan D, and Kertesz A.

The diagnosis of mixed dementias in the Consortium for the Investigation of Vascular Impairment of Cognition (CIVIC) in Kalaria RN, and Ince P. Annals of the New York Academy of Sciences 2000; 903: 522-528.

127. Munoz D and Feldman H. Causes of Alzheimer’s Disease. Canadian Medical Association Journal 2000; 161(1):

65-72. 128. Gauthier S, Rockwood K, Gelinas I, Sykes L, Teunisse S, Orgogozo JM, Erkinjuntti T, Erzigkeit H, Gleeson M,

Kittner B, Pontecorvo M, Feldman H, and Whitehouse P. Outcome Measures for the Study of Activities of Daily Living in Vascular Dementia. Alzheimer Disease & Associated Disorders 1999; 13(3): S143-S147.

129. Patterson C, Gauthier S, Bergman H, Cohen C, Feightner J, Feldman H, and Hogan D. Canadian Consensus on

Dementia: A Physician’s Guide to Using the Recommendations. Canadian Medical Association Journal 1999; 160: 1738-1742.

130. Patterson C, Gauthier S, Bergman H, Cohen C, Feightner J, Feldman H, and Hogan D. The Recognition,

Assessment and Management of Dementing Disorders: Conclusions from the Canadian Consensus Conference on Dementia. Canadian Medical Association Journal 1999; 160(Suppl. 12): S1-S15.

131. Whitehouse PJ, Winblad B, Shostak D, Bhattacharjya A, Brod M, Brodaty H, Dor A, Feldman H, Forette F, Gauthier

S, Hay J, Hill S, Mastey V, Neumann P, O’Brien B, Pugner K, Sano M, Sawada T, Stone R, and Wimo A. First International Pharmacoeconomic Conference on Alzheimer’s Disease: Report and Summary. Alzheimer’s Disease & Associated Disorders 1998; 12: 266-280.

132. Lanius RA, Wagey R, Sahl B, Beattie BL, Feldman H, Pelech SL, and Krieger C. Protein Kinase C Activity and

Protein Levels in Alzheimer’s Disease. Brain Research 1997; 754: 75-80. 133. Rockwood K, Beattie BL, Eastwood R, Feldman H, Mohr E, Pryse-Phillips W, and Gauthier S. A Randomized,

Controlled Trial of Linopirdine in the Treatment of Alzheimer’s Disease. Canadian Journal of Neurological Sciences 1997; 24:140-145.

134. Claus JJ, van Gool WA, Feldman H, and Mohr E. The Clinical Utility of Brain SPECT in Alzheimer’s Disease: A

Critical View of the Report By the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1997 Apr.; 48 (4): 1139-1140.

135. Feldman H, Anand R, Dubois B, Gray J, Mohr E, Morris JC, Parys W, Raschig A, and Robillard A. Translation

Issues in Clinical Trials for Alzheimer’s Disease. Alzheimer’s Disease & Associated Disorders 1997; 11(3): 61-64. 136. Reisberg B, Schneider L, Doody R, Anand R, Feldman H, Haraguchi H, Kumar R, Lucca U, Mangone CA, Mohr E,

Morris JC, Rogers S, and Sawada T. International Working Group on Harmonization of Dementia Drug Guidelines: Consensus Statement on Clinical Global Measures. Alzheimer’s Disease & Associated Disorders 1997; 11(3): 8-18.

137. Gauthier S, Bodick N, Erzigkeit E, Feldman H, Geldmacher DS, Huff J, Mohs R, Orgogozo JM, and Rogers S.

Activities of Daily Living as an Outcome Measure in Clinical Trials of Dementia Drugs. Alzheimer’s Disease & Associated Disorders 1997; 11(3): 6-7.

41

138. Mattman A, Feldman H, Forster B, Li D, Szasz I, and Schulzer M. Regional HmPAO SPECT and CT

Measurements in the Diagnosis of Alzheimer’s disease. Canadian Journal of Neurological Sciences 1997; 24: 22-28.

139. Kennard ML, Feldman H, Yamada T, and Jefferies WA. Serum Levels of the Iron Binding Protein p97 Are Elevated

in Alzheimer’s Disease. Nature Medicine 1996; 2 (11): 1-6. 140. Gauthier S, Montplaisir J, Petit D, Joanette Y, Feldman H, Mohr E, Nair NPV, and Poirier J. Outcome Variables in

Pre-symptomatic Individuals at Higher Risk of Developing Alzheimer’s Disease. Alzheimer’s Disease & Associated Disorders 1996; 10(Suppl. 1): 19-21.

141. Mohr E*, Feldman H*, and Gauthier SG. Canadian Guidelines for the Development of Antidementia Therapies: A

Conceptual Summary. Canadian Journal of Neurological Sciences 1995; 22: 62-71. (* co-first authors) 142. Uitti RJ, Berry K, Yasuhara O, Eisen A, Feldman H, McGeer PL, and Calne DB. Neurodegenerative "Overlap

Syndrome": Clinical and Pathological Features of Parkinson's Disease, Motor Neuron Disease and Alzheimer’s Disease. Parkinsonism & Related Disorders 1995; 1(1): 21-34.

143. Earnest MP, Feldman H, and Marks JA. Intracranial Lesions Shown by Computerized Tomographic Scanning in

259 Patients With First Alcohol Related Convulsions. Neurology 1988: 38: 1561-1566. REFEREED PUBLICATIONS (b) Journals – Investigator As Part of Collaborative Studies Published in PubMed 144. Pearson SD, Ollendorf DA, Colby JA and the Alzheimer’s Diagnostics Policy Development Group (H Feldman)

Biomarker Tests for the Diagnosis of Alzheimer’s Disease: Generating Evidence to Inform Insurance Coverage Determinations; Alzheimer’s and Dementia, 2013 in press

145. Vellas B, Hampel H, Rouge-Bugat ME, Grundman M, Andrieu S, Abu-Shakra S, Bateman R, Berman R, Black R, Carrillo M, Donahue M, Mintun M, Morris J, Petersen R, Thomas RG, Suhy J, Schneider L, Seely L, Tariot P, Touchon J, Weiner M, Sampaio C, Aisen P, Task Force Participants (Feldman H): Alzheimer’s Disease Therapeutic Trials: EU/US Task Force Report on Recruitment, Retention and Methodology J Nutr Health Aging. 2012 Apr;16(4): 339-45 [PMID 22499454]

146. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winbald B,

(Feldman H). Current concepts in mild cognitive impairment. Archives of Neurology 2001; 58(12):1985-1992.

147. Wilcock GK, Lilienfeld S, and Gaens E on behalf of the Galantamine International-1 Study Group (Feldman H). Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. British Medical Journal 2000; 321: 1445-1449.

148. McDowell I, The Canadian Study of Health and Aging Working Group (Feldman H). The Incidence of Dementia in

Canada. Neurology 2000; 55: 66-73.

149. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, Rogers SL, Friedhoff LT, International Donepezil Study Group (Feldman H). The Effects of Donepezil in Alzheimer's Disease - Results from a Multinational Trial. Dementia & Geriatric Cognitive Disorders 1999; 10: 237-244.

42

WORK SUBMITTED: Peer Reviewed Journals (under review or revision for publication)

150. Hallam BJ, Jacova C, Hsiung GY R, Wittenberg D, Sengdy P, Bouchard-Kerr P, Slack P, Rademakers R, Baker M,

Chow TW, Levine B, Feldman HH and Mackenzie IRA Neuropsychological Characteristics in Predementia Progranulin Mutation Carriers. First submission to Dementia and Geriatric Cognitive Disorders March 23, 2013

151. Omoumi A, Fok A, Greenwood T, Sadovnick AD, Feldman HH, Hsiung RH Evaluation of late-onset Alzheimer’s disease genetic susceptibility risks in Canadian population Neurobiology of Aging, first reviews July 13, 2013 and revisions

NON-REFEREED PUBLICATIONS (a) Journals 1. Woodward M, Mackenzie IRA, Hsiung G-YR, Jacova C, Feldman H; Multiple Brain Pathologies in Dementia Are

Common. European Geriatric Medicine 1 (2010) 259-265 2. Feldman H and Qadi N. Addressing Severe Alzheimer’s Disease: A Clinical Approach. Canadian Review of

Alzheimer’s Disease & Other Dementias 2006; 8(3): 4-9.

3. Hsiung G-YR, Alipour S, Jacova C, Donald A, and Feldman H. Functional impairment associated with progression from CIND to Alzheimer’s Disease. Research and Practice in Alzheimer’s Disease 2006; 11: 179-183.

4. Feldman H and Beattie BL. The New Era of Treatable Alzheimer Disease: ending a dark age in British Columbia.

British Columbia Medical Journal (BCMJ) 2004; 46(7): 332-333. 5. Feldman H. Rethinking the Diagnostic and Treatment Approach to Alzheimer's Disease: A Fresh Look. British

Columbia Medical Journal (BCMJ) 2004; 46(7): 334-337. 6. Feldman H and Beattie BL. Treatment Efficacy in Alzheimer Disease (TREAD). British Columbia Medical Journal

(BCMJ) 2004; 46(7): 344-347.

7. Hsiung G-YR and Feldman H. A Review of the Diagnosis and Assessment of Dementia. Geriatrics & Aging. 2004 Jul.; 7(8 Suppl): 9-15.

8. Hsiung G-YR and Feldman H. Pharmacological Management of Alzheimer Disease: an update. Geriatrics & Aging.

2004 Feb.; 7(2): 47-50. 9. Loy-English I and Feldman H. The Emerging Spectrum of the Parkinsonian Dementias. Canadian Alzheimer

Disease Review 2004 Sep.; 7(2): 9-12. 10. Feldman H. The Clinical Management of Early Alzheimer's Disease. Canadian Journal of Neurological Sciences

(book review) 2003 Nov.; 30(4): 412. 11. Loy-English I and Feldman H. Vascular Dementia: The beginning of a new era. Canadian Alzheimer Disease

Review. 2003 Sept.; 6(1): 4-8. 12. Scholes R and Feldman H. Neurobiology of Alzheimer’s Disease. GERIATRICS Today: Journal of the Canadian

Geriatrics Society (book review) 2001 Nov.; 4(4): 201-202.

43

13. Feldman H. Alzheimer’s Disease: Methods and Protocols. Canadian Journal of Neurological Sciences (book

review) 2000; 27: 355-356. 14. Patterson CJS, Gauthier S, Bergman H, Cohen C, Feightner J, Feldman H, Grek AJ, and Hogan D. Can We

Improve Primary Medical Care of People With Dementia? Mature Medicine Canada 1999; 219-222. 15. Feldman H. The New Face of Alzheimer’s Disease: Overcoming Therapeutic Nihilism. Canadian Journal of

Diagnosis 1999; 16(12): 1-2. 16. Feldman H. Caregiver Burden: An Important Concept in the Management of Alzheimer’s Disease. Alzheimer

Insights 1999; 5(4): 1-4. 17. Feldman H. Alzheimer’s Disease: Update 1995. British Columbia Medical Journal (BCMJ) 1995; 37(4): 257-262. WORK SUBMITTED: Non Peer Reviewed Journals (under review or revision for publication) PUBLISHED SCIENTIFIC ABSTRACTS (a) Peer Reviewed Journals

1. Jacova C., Hsiung GYK, De Jesus Hernandez, M, Sengdy P, Bouchard Kerr P, McCormick S, Dinelle Km, Sossi V,

Rademakers R, Stoessl A Jon, Feldman HH Mackenzie I; 8th International Conference on Frontotemporal Dementias Manchester UK p 330

2. Hsiung GYK, DeJesus Hernandez M, Feldman HH, Qadi N, HJacova C, Sengdy P, Bouchard Kerr P, Rademakers R, and Mackenzie IR Comparison of Clinical features in FTD due to GRN and C9ORF mutations 8th International Conference on Frontotemporal Dementias Manchester UK p 65

3. Youn YC, Jacova C, Jang JW, Sengdy P, Kee BS, Feldman H, Rademakers R, Mackenzie I, Hsiung GY. Longitudinal Gray and White Matter Changes in Progranulin Mutation Carriers at Risk for FTD: A VBM Study Alzheimer’s & Dementia v 8 (4) Suppl 2, p689, July 2012 (P4-155)

4. Coric V, Colby S, Hazel J, Lipschitz A, Kaplita S, Feldman H, Bratt T, Berman R Avagacestat for Predementia Alzheimer’s Disease: Methods and Baseline Results Alzheimer’s & Dementia v 8 (4) Suppl 2,p408, July 2012 (P2-413)

5. Bracoud L, Coric V, van Dyck C, Andreasen N, Ross J, Brody M, Curtis C, Boubakeur B, Yu HJ, Kaplita S, Feldman H, Pachai C, Berman R Alzheimer’s & Dementia v 8 (4) Suppl 2,p 409 July 2012 (P2-414)

6. Hsiung GY-R, DeJesus-Hernandez M, Feldman HH, Sengdy P, Bouchard Kerr P, Dwosh E, Butler R, Leung B, Fok A, Rutherford NJ, Baker M, Rademakers R, Mackenzie IRA Clinical Heterogeneity in Familial Frontotemporal Dementia and Amyotrophic Lateral Sclerosis Caused by C9ORF72 Mutation Neurology 2012, 78 (s54)

7. Sperling RA, Bronen RA, Greenberg SM, Sorensen AG, Salloway S, Gass A, Meadowcroft MD, Berman RM, Albright CF, Coric V, Feldman HH. Three cases of apparent vasogenic edema from a Phase 2 clinical trial of the gamma-secretase inhibitor BMS-708163 in patients with mild-to-moderate Alzheimer’s Disease. Alzheimer’s & Dementia 2011; 7(4): PS377

44

8. Salloway S, Coric V, Brody M, Andreasen N, van Dyck CH, Soininen H, Thein S, Shiovitz T, Kumar S, Pilcher G,

Colby S, Rollin L, Feldman HH, Berman RM. Safety and Tolerability of BMS-708163 in a Phase 2 Study in Mild-to-Moderate Alzheimer’s Disease (AD). Alzheimer’s & Dementia 2011; 7(4): PS695-S696.

9. Coric V, Seibyl J, Mintun M, Ross J, Brody M, Curtis C, Richter R, Hayes W, McHugh B, Yoo B, Marek K, Grill JD,

Feldman HH, Berman R. Correlation between baseline measures of amyloid-positron emission tomography (PET) imaging, cerebral spinal fluid (CSF) biomarkers, and clinical scales in predementia Alzheimer’s Disease (AD). Alzheimer’s & Dementia 2011; 7(4): PS209.

10. Albright CF, Andreasen N, Minthon L, Blennow Kaj, Feldman HH, Soares H, Berisha F, Rhyne P, Rollin L, Coric V,

Berman RM. The gamma-secretase inhibitor BMS-708163 causes dose-dependent reductions in CSF Aβ40 levels in patients with mild-to-moderate Alzheimer’s Disease (AD). Alzheimer’s & Dementia 2011; 7(4): PS311.

11. Kingery LR, Bartolic E, Meyer S, Perez M, Bertzos K, Hazel J, Feldman HH, Berman RM, Coric V. Test-retest

reliability of the MMSE, ADAS-Cog, and executive function tests in a Phase II mild-to-moderate Alzheimer’s Disease study. Alzheimer’s & Dementia 2011; 7(4): PS249.

12. Veroff AE, Babic T, Coric V, Berman RM, Feldman HH. Towards more strategic subject selection in Alzheimer’s

randomized clinical trials: Neuropsychological testing to distinguish fast decliners from improvers. Alzheimer’s & Dementia 2011; 7(4): PS276-S277.

13. Portelius E, Blennow K, Andreasson U, Zetterberg H, Soares H, Simon A, Slemmon R, Albright C, Tong G, Burns L,

Berisha F, Rhyne P, Coric V, Feldman H, Berman R. The gamma secretase inhibitor, BMS-708163, increases alpha secretase Abeta peptide cleavage fragments and decreases the gamma secretase Abeta peptide 1-34 fragment in cerebrospinal fluid. Alzheimer’s & Dementia 2011; 7(4): PS289.

14. Limsoontarakul S. Jacova C, Hsiung GR, Leung B, Christoff K, Feldman H, Mackenzie I, Hallam B Matrix

Reasoning in Presymptomatic Progranulin Carriers Alzheimer’s & Dementia 2011:7 (4) Supp 1, S763

15. Feldman HH, Coric V, Sperling RA, Greenberg SM, Bronen RA, Sorensen AG, Salloway S, Pachai C, Kaplita S, Meadowcroft MD, Albright CF, Berman RM. Cerebral microbleeds in a Phase 2 clinical trial of mild-to-moderate Alzheimer’s Disease with the gamma-secretase inhibitor BMS-708163. Alzheimer’s & Dementia 2011; 7(4): P375.

16. Burns L, Hsiung GYR, Money J, Guo Z, L’Italien G, Berman RM, Budd D, Feldman HH. Relationship between

caregiver engagement and severity of cognitive impairment in early Alzheimer’s Disease (AD). Alzheimer’s & Dementia 2011; 7(4): PS428-S429.

17. Hsiung G-YR, Vostretsova K, Jacova C, Money J, Feldman H, ACCORD Investigators. Risk Factors Associated

with Nursing Home Placement in Cognitive Impairment Not Dementia (CIND) and Dementia Patients: Data from the Accord Study. Alzheimer’s & Dementia 2010; 6(6 S1): P S117

18. Burns L, L’Italien G, Guo Z, Lapuerta P, Risinger R, Berman RM, Kaplita S, Hill D, Feldman H, Rueckert D,

Donohue M. Predicting Time to Dementia Based on Selected MRI Volumetrics and CSF Measures. Alzheimer’s & Dementia 2010; 6(6 S1): P S284.

19. Risinger R, Berman RM, Coric V, Han J, Kaplita S, Burns L, Bhagwagar Z, Hill D, Wolz R, Rueckert D, Feldman H.

Mild to Moderate Alzheimer’s Disease (AD) Clinical Trials: The Role of Hippocampal Atrophy as an Inclusion Criterion. Alzheimer’s & Dementia 2010; 6(6 S1): P S285.

20. Jacova C, Hyunsoo SL, Le Huray S, McGrenere J, Beattie BL, Feldman H, Hsiung, G-YR. Cognitive Testing on

Computer (C-TOC): Designing a Computerized Test Battery for Evaluation of Cognitive Impairment with User and Community Health Professional Input. Alzheimer’s & Dementia 2010; 6(6 S1): P S317.

21. Tawankanjanachot I, Jacova C, Hsiung G-YR, Hyunsoo SL, McCormick S, Dinelle K, Sossi V, Sengdy P,

Rademakers R, Baker MC, Stoessl AJ, Feldman HH, Mackenzie IR. (18) F-Fluorodeoxyglucose Positron Emission Tomography in Presymptomatic Progranulin Mutation Carriers. Alzheimer’s & Dementia 2010; 6(6 S1): P S427.

45

22. Veroff AE, Perez M, Bertzos K, Brady C, Hazel J, Watson-Coleman O, Coric V, Berman R, Feldman H. Adas-Cog Central Monitoring and Intervention with Raters: A Critical Extension and Integral Component of Alzheimer Trials Rater Training Programs. Alzheimer’s & Dementia 2010; 6(6 S1): P S483.

23. Perez M, Bertzos K, Brady C, Hazel J, Watson-Coleman O, Berman R, Coric V, Feldman HH, Veroff AE. The

Relationship Between Rater Experience and Performance on Certification Exercises and Study Subject Ratings in an Alzheimer Trial. Alzheimer’s & Dementia 2010; 6(6 S1): P S486

24. Burns L, L’Italien G, Guo Z, Lapuerta P, Berman RM, Kaplita S, Feldman H, Donohue M. Exploring CSF Biomarker

Cutpoints with Penalized Spline Analysis and Maximized Log Rank Test. Alzheimer’s & Dementia 2010; 6(6 S1): P S508

25. Petkau T, Neal SJ, Milnerwood A, Orban PC, Feldman HH, Raymond L, Mackenzie, IRA. Generation and

Characterization of a Mouse Mode of Progranulin Deficiency. Alzheimer’s & Dementia 2010; 6(6 S1): P S65 26. Hsiung GR, Fok A, Feldman HH, Rademaker R, and Mackenzie IRA. Serum progranulin is influenced by rs5848

SNP at the miR-659 binding site of the GRN gene. Canadian Journal of Geriatrics 2009; 12(3): 125. 27. Jacova C, Schulzer M, Money J, Kupferschmidt AL, Beattie BL, and Feldman HH. Social impact as a novel

construct in the measurement of clinically meaningful change: Validation data for the Clinical Meaningfulness in Alzheimer Disease Treatment (CLIMAT) scale. Canadian Journal of Geriatrics 2009; 12(3): 131.

28. Hsiung GYR, Kupferschmidt AL, Naus K, Feldman HH, and Jacova C. Does BrainAge affect a brain’s age? A pilot

study on computerized cognitive training in mild cognitive impairment. Canadian Journal of Geriatrics 2009; 12(3): 124.

29. Butler R, Beattie L, Dwosh E, Feldman H, Guimond C, Hsiung G-YR, PuangThong U, George-Hyslop, Rogaeva E,

and Sadovnick AD. A novel PS1 mutation in a large aboriginal kindred with early onset familial Alzheimer’s disease from a remote community in northern British Columbia. Alzheimer’s & Dementia 2009; 5(4 S1): P149-150.

30. Hsiung GR, Fok A, Feldman HH, Rademaker R, and Mackenzie IRA. Serum progranulin is reduced in GRN

mutation carriers but not in other dementia. Alzheimer’s & Dementia 2009; 5(4 S1): P342. 31. Woodward M, Jacova C, Mackenzie IR, Feldman H, Kertesz A, Black S, and the ACCORD Investigator Group.

Differentiating the frontal variant of Alzheimer’s disease. Alzheimer’s & Dementia 2009; 5(4 S1): P187. 32. Hsiung G-YR, Kupferschmidt AL, Naus K, Feldman H, and Jacova C. Cognitive and clinical outcomes in a pilot

study using a handheld computer game for cognitive training of patients with mild cognitive impairment. Alzheimer’s & Dementia 2009; 5(4 S1): P411.

33. Jacova C, Schulzer M, Money J, Deria S, Kupferschmidt AL, Beattie BL, and Feldman H. Social impact in the

measurement of clinically meaningful change: Findings from the cross-sectional validation of the Clinical Meaningfulness in Alzheimer Disease Treatment (CLIMAT) scale. Alzheimer’s & Dementia 2009; 5(4 S1): P188.

34. Jacova C, Schulzer M, Money J, Deria S, Kupferschmidt AL, Beattie BL, and Feldman H. Cross-sectional validation

of a new instrument for the measurement of treatment response: The Clinical Meaningfulness in Alzheimer Disease Treatment (CLIMAT) scale. Alzheimer’s & Dementia 2009; 5(4 S1): P184.

35. Hsiung GR, Fok A, Feldman HH, Rademaker R, and Mackenzie IRA. Reduced serum progranulin in GRN mutation

carriers. Neurology 2009; 72(S3): A410. 36. Feldman HH, Jones RW, Kivipelto M, Sparks L, Doody R, Waters D, Hey-Hadavi J, Breazna A, Schindler RJ, and

Ramos H. The LEADe Study: A Randomized, Controlled Trial Investigating the Effect of Atorvastatin on Cognitive and Global Function in Patients with Mild-to-Moderate Alzheimer’s Disease Receiving Background Therapy of Donepezil. Neurology 2008; 71: 154.

37. Hsiung G-YR, Feldman HH, and Mackenzie IRA. Comparison of clinical and pathological diagnoses in a

specialized dementia clinic cohort. Alzheimer’s & Dementia 2008; 4(4) Suppl. 1: T521.

46

38. Kandiah N, Jacova C, Schulzer, and Feldman HH. Characterizing longitudinal change in cognition and activities of daily living among subjects with stable Mild Cognitive Impairment: The investigation to delay the diagnosis of AD with Exelon (InDDEx) study. Alzheimer’s & Dementia 2008; 4(4) Suppl. 1:T562-T563.

39. Sadovnick AD, Dwosh E, Guimond C, Beattie BL, Feldman HH, Hsiung G-YR, and Butler R. Genetic counselling

issues involving a novel PS1 gene change in a large first nations kindred form a remote community in Northern British Columbia. Alzheimer’s & Dementia 2008; 4(4) Suppl. 1: T598.

40. Jacova C, Kandiah N, Schulzer, and Feldman HH. Quality of life in Mild Cognitive Impairment that does not

progress to Alzheimer disease: Longitudinal analyses of the investigation to delay the diagnosis of Alzheimer’s disease with Exelon (InDDEx) study. Alzheimer’s & Dementia 2008; 4(4) Suppl. 1: T646-T647.

41. Ayoub OA, Grand J, Jacova C, Money J, Feldman HH, and Hsiung G-YR. Risk factors influencing survival in

Alzheimer’s disease: Analysis from a single center in the Canadian cohort study of cognitive impairment and related dementias (ACCORD). Alzheimer’s & Dementia 2008; 4(4) Suppl. 1: T668.

42. Feldman HH, Cummings J, Schwam E, Jones RW, Wilkinson D, Waldemar G, Zhang R, and Schindler R.

Evaluating neuropsychiatric symptoms in Alzheimer’s disease: A novel approach using bubble plots to evaluate donepezil treatment effects. Alzheimer’s & Dementia 2008; 4(4) Suppl. 1: T763-T764.

43. Gauthier S, Lopez O, Schwam E, Feldman HH, Waldemar G, Jones RW, Wilkinson D, Zhang R, and Schindler R.

Impact of donepezil therapy on function in relation to MMSE in patients with Alzheimer’s disease. Alzheimer’s & Dementia 2008; 4(4) Suppl. 1: T781.

44. Wilkinson D, Schwam E, Feldman HH, Waldemar G, Jones RW, Xu Y, and Schindler R. Donepezil therapy for

patients with Alzheimer’s disease: Treatment benefits in “non-responders”. Alzheimer’s & Dementia 2008; 4(4) Suppl. 1: T793.

45. Jones R, Schwam E, Wilkinson D, Waldemar G, Feldman HH, Zhang R, and Schindler R. Variation in placebo

declines across a decade of Alzheimer’s disease trials. Alzheimer’s & Dementia 2008; 4(4) Suppl. 1: T334. 46. Feldman HH. Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD). Journal of Neurology 2008; 255(S2):

4. 47. Brooks BL, Iverson GL, Holdnack JA, and Feldman HH. Psychometric Misdiagnosis of Amnestic MCI in Healthy

Older Adults: Part I. WMS-III Primary and Index Scores. Archives of Clinical Neuropsychology 2007; 22(7): 881.

48. Brooks BL, Iverson GL, Holdnack JA, and Feldman HH. Psychometric Misdiagnosis of Amnestic MCI in Healthy

Older Adults: Part II. An Abbreviated WMS-III Battery. Archives of Clinical Neuropsychology 2007; 22(7): 881. 49. Hsiung G-YR, Alipour S, Jacova C, Feldman HH, for the ACCORD Investigators. Transition from Cognitive

Impairment Not Dementia to Alzheimer’s Disease: An analysis of changes in functional abilities. Neurology 2007; 68(12): Suppl. 1: A234.

50. Yeo LHJ, Hallam B, Qadi N, Hsiung G-YR, Dwosh E, Sadovnick D, Lindholm C, Baker M, Pickering-Brown S,

Hutton M, Mackenzie IRA, and Feldman HH. Progranulin mutations in frontotemporal dementia: A study of 6 families with different mutations. Neurology 2007; 68(12) Suppl. 1: A350.

51. Peters KR, Hsiung GR, and Feldman HH. Apolipoprotein E genotype in Cognitively-Impaired-Not-Demented

Individuals. Journal of the International Neuropsychological Society 2006; 12(S1): 52. 52. Qadi N, Hsiung G-YR, Mackenzie IRA, Hutton M, Pickering-Brown S, and Feldman HH. FTD with Ubiquinated

Inclusions: Clinical and Neuropathological Variation Associated with a Common Haplotype at Chromosome 17q21. Neurology 2006; 66(5) Suppl. 2: A200.

53. Jacova C, Hsiung G-YR, Peters KR, Hayden S, and Feldman HH, for the ACCORD Investigators. Progression to

Dementia and Recovery to Normal Functioning in Cognitive-Impairment-No-Dementia (CIND) Have Unique Neuropsychological Predictors. Neurology 2006; 66(5) Suppl. 2: A346.

47

54. Feldman H. Neuropsychiatric symptoms in AD: Changing treatment algorithms. European J Neurol. 2006;

13(Suppl. 2): 319. 55. Feldman H. Lessons to be learned from the studies in mild cognitive impairment and early Alzheimer’s disease.

Alzheimer's & Dementia 2006; 2(3) Suppl. 1: S45. 56. Alipour S, Jacova C, Hsiung G-YR, Donald A, Feldman H, and the ACCORD Study Investigators. An evaluation of

functional disability in mild cognitive impairment: Baseline impairment does not predict progression in the ACCORD study. Alzheimer's & Dementia 2006; 2(3) Suppl. 1: S288-S289.

57. Jacova C, Schulzer M, Beattie BL, and Feldman HH. The impact of neuropsychological norms and cutoff points on

amnestic and multidomain subtype classification in Cognitive-Impairment-No-Dementia (CIND). Alzheimer's & Dementia 2006; 2(3) Suppl. 1: S380.

58. Woodward M, Mackenzie IR, and Feldman H. High prevalence of multiple brain pathologies in dementia. Alzheimer's & Dementia 2006; 2(3) Suppl. 1: S426.

59. Qadi N, Mackenzie IRA, Dwosh ES, and Feldman HH. Frontotemporal degeneration with ubiquinated inclusions: A

case report of a family with corticobasal syndrome and prominent parietal degeneration. Alzheimer's & Dementia 2006; 2(3) Suppl. 1: S549.

60. Hsiung G-YR, Mackenzie I, Lindholm C, and Feldman H. Frontotemporal lobar degeneration with ubiquitin-positive

inclusions: Demographics and survival analysis of clinical subgroups. Alzheimer's & Dementia 2006; 2(3) Suppl. 1: S549.

61. Yip S, DiMaio S, Mackenzie I, Moore W, Heran M, Graeb D, Kavanagh E, Smyth P, and Feldman H. Granulomatous angiitis associated with cerebral amyloid angiopathy: a case report. Canadian Journal of Neurological Sciences 2006; 33(S1): S31.

62. Peters KR, Graf P, Hayden SL, and Feldman HH. Neuropsychological Subgroups of Cognitively-Impaired-Not-

Demented Individuals. Journal of the International Neuropsychological Society 2005; 11(S1): 154. 63. Hsiung GR, Jacova C, Feldman H, and ACCORD Investigators. Neuropsychological deficits and leukoaraiosis are

independent predictors of progression from CIND to dementia. Geriatrics Today 2005: 8(3): 119. 64. Feldman HH, Hsiung G-YR, Jacova C, and Donald A. Cognitive Impairment Not Dementia (CIND): Does Etiology

Matter? Findings from the ACCORD Study. Journal of the International Neuropsychological Society 2005; 11(S1): 155.

65. Feldman H, Gauthier S, Hecker J, Vellas B, Leni J, Xu Y, and Schwam E. Treatment Benefits of Donepezil in

Patients with Severe Alzheimer’s Disease & Their Caregivers. Neurology 2005; 64 (6 S1): A105. 66. Feldman H, Schmitt FA, Doraiswamy PM, Graham SM, and Bell JM. Memantine and Individual Activities of Daily

Living in Moderate to Severe Alzheimer’s Disease. Neurology 2005; 64 (6 S1): A103. 67. Jacova C, Hamm F, Peters KR, Hayden S, Beattie BL, and Feldman H. Semantic Memory and Verbal Reasoning

Deficits are Neuropsychological Features of Amnestic Cognitively-Impaired-Not-Demented (CIND) Subjects. Neurology 2005; 64(6 S1): A65.

68. Hsiung G-YR, Rockwood K, and Feldman H for the ACCORD Investigators Group. Presence of Leukoaraiosis and

diffuse Brain Atrophy predicts progression of Cognitively Impaired Not Demented (CIND) to Dementia. 2nd Congress of the International Society for Vascular Behavioural and Cognitive Disorders (VAS-COG). 2005: 19.

69. Rockwood K, Black S, and Feldman H. Progression to dementia in patients with vascular cognitive impairment

without dementia: a multi-centre clinical study. 2nd Congress of the International Society for Vascular Behavioural and Cognitive Disorders (VAS-COG). 2005: 105.

48

70. Feldman H, Jacova C, and Schulzer M. The role of residential setting in determining the risk of cognitive impairment and dementia. Alzheimer's & Dementia 2005; 1(S1): S76-S77.

71. Jacova C, Hsiung G-YR, Peters KR, Feldman HH and the ACCORD Investigators. Compliance with

Neuropsychological Testing May Lead to Underestimation of Decline in Cognitively-Impaired-Not-Demented (CIND) Individuals. Alzheimer's & Dementia 2005; 1(S1): S77.

72. Hsiung G-YR, Donald A, Jacova C, Feldman HH and the ACCORD Investigators. Loss of Initiation and Planning

Predicts Progression from CIND to Alzheimer’s Disease. Alzheimer's & Dementia 2005; 1(S1): S80. 73. Feldman HH, van Baelen B, and Kavanagh S. Effects of galantamine on activities of daily living in people with

Alzheimer's disease: Evidence from six placebo-controlled trials. 9th Congress of the European Federation of Neurological Sciences 2005.

74. Feldman H, Schmitt F, Pfeiffer E, Graham S, and Bell J. Memantine and individual activities of daily living in

moderate to severe Alzheimer’s disease. International Psychogeriatrics 2005; 17 (S2): 200. 75. Ferris S, Feldman H, Sfikas N, Mancione L, and Lane R. Time to clinical diagnosis of dementia in MCI subjects

receiving rivastigmine: a randomized, double-blind, placebo-controlled study. International Psychogeriatrics 2005; 17 (S2): 243.

76. Van Baelen B, Feldman H, and Kavanagh S. Activities of daily living in mild to moderately-severe Alzheimer’s

disease: Evidence from six placebo-controlled trials of galantamine. International Psychogeriatrics 2005; 17 (S2): 315.

77. Feldman H. Outcome measures in clinical trials. International Psychogeriatrics 2005; 17 (S2): 74. 78. Feldman H. Cerebral Amyloid Angiopathy: A key to the future of Alzheimer’s disease. 4th International Congress on

Vascular Dementia 2005. 79. Feldman H, Schmitt FA, Pfeiffer E. Graham SM, and Bell JM. Memantine and individual activities of daily living in

moderate to severe Alzheimer's disease. European Neuropsychopharmacology 2005; 15(S3): S570. 80. Feldman H and Mackenzie IRA. Clinicopathological Vignettes. 3rd Canadian Colloquium on Dementia (CCD) 2005. 81. Feldman H. Therapy of vascular and mixed dementia. 18th World Congress of Neurology. 2005. 82. Feldman H. Current symptomatic treatment for Alzheimer’s disease.18th World Congress of Neurology. 2005. 83. Hsiung R, Donald A, Grand J, and Feldman H. Predictors of outcome of Cognitive Impairment Not Dementia

(CIND) at 2-years in the Canadian Collaborative Cohort of Related Dementias (ACCORD). Neurobiology of Aging 2004; 25 (S2): S74.

84. Grand J, Hsiung R, Donald A, Mackenzie IRA, and Feldman H. Longitudinal Rates of Decline of the Spectrum of

Degenerative Dementias: Findings from the Canadian Collaborative Cohort Study of Related Dementias (ACCORD). Neurobiology of Aging 2004; 25 (S2): S96.

85. Feldman H, Charbonneau C, Lescrauwaet B, Donald A, and Petit P. Using a Canadian Observational Study

(ACCORD) to Model the Economic Impact of Alzheimer’s Disease (AD) Treatment. Neurobiology of Aging 2004; 25 (S2): S478.

86. Feldman H. Treating Alzheimer’s Disease: The challenge of treating the spectrum of severity from mild to severe.

Neurobiology of Aging 2004; 25 (S2): S91. 87. Feldman H, Scheltens P, Scarpini E, Mancione L, and Lane R. Operational Criteria for Confirmation of Clinical

Diagnosis of Alzheimer’s Disease in Patients with Initial Symptoms of Mild Cognitive Impairment (MCI). Neurobiology of Aging. 2004; 25 (S2): S472.

49

88. Feldman H, Van Baelen B, and Kavanagh S. Long-term Treatment with Galantamine in Patients with Alzheimer’s Disease and Alzheimer’s Disease with Cerebrovascular Disease. Neurobiology of Aging 2004; 25 (S2): S198.

89. Sachak S, Feldman H, Zhu Y, Amatniek J, and Mahableshwarkar A. Patterns of Neuropsychiatric Symptoms in

Alzheimer’s Disease, Mixed Dementia, and Vascular Dementia. Neurobiology of Aging 2004; 25 (S2): S221. 90. Shah SN, Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, Schwam E, and Leaderer M.

Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer’s disease. Neurobiology of Aging 2004; 25 (S2): S208.

91. Gauthier S, Surh L, Gibson R, Borrie M, Delisle R, Feldman H, Fornazzari L, Guzman D, Khatchaturian Z, Keren R,

Kertesz A, Loy-English I, St George-Hyslop P, Pryse-Phillips W, and Wherrett J. A Canadian Study on the Genetics of Late-onset Alzheimer’s Disease Associations: ‘GenADA’. Neurobiology of Aging 2004; 25 (S2): S138.

92. Fornazzari L, Nadkarni S, Surh L, Newton R, Salvarrey A, Apanasiewicz N, Miranda D, St George-Hyslop P, Borrie

M, Feldman H, Gauthier S, Gibson R, Guzman A, Keren R, Kertesz A, Loy-English I, Pryse-Phillips W, Wherrett J, and Hsiung R. Inter-rater reliability of neuropsychological assessments used in the Canadian Study on Genetics of Alzheimer’s Disease Associations (GenADA). Neurobiology of Aging 2004; 25 (S2): S323.

93. Hsiung R, Donald A, Grand J, and Feldman H. Cognitive Impairment Not Demented (CIND): 2-year outcome study

from the ACCORD. Neurology 2004; 62(7) Suppl. 5: A87. 94. Hsiung R, Shobab L, Grand J, and Feldman H. Interaction between statin usage and Apolipoprotein E in risk of

developing Alzheimer’s disease: data from the ACCORD study. Neurology 2004; 62(7) Suppl. 5: A211. 95. Jacova C and Feldman H. Screening for Cognitive-Impairment-No-Dementia (CIND): The predictive utility of the

Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Neurology 2004; 62(7) Suppl. 5: A131.

96. Jacova C, Peters KR, Beattie BL, Foti D, and Feldman H. Screening for Cognitive-Impairment-No-Dementia

(CIND): The predictive utility of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Journal of the American Geriatrics Society 2004; 52 (S1): S156.

97. Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Schwam, Leaderer M, and Shah SN. Pharmacoeconomic

benefits of donepezil treatment in severe Alzheimer’s disease. Journal of the American Geriatrics Society 2004; 52 (S1): S149.

98. Jacova C, Eadie B, Beattie BL, Peters KR, and Feldman H. Short-term decline in Cognitively-Impaired-Not-

Demented (CIND) subjects affects language and delayed memory. Canadian Journal of Neurological Sciences 2004; 31(S1): S42.

99. Peters KR and Feldman H. Further Characterization of Memory Impaired Subgroups of Cognitively-Impaired-Not-

Demented Individuals from the ACCORD Study. Journal of the International Neuropsychological Society 2004. 100. Rockwood KR and Feldman H. The Outcomes of Patients with Vascular Cognitive Impairment in relation to other

Memory Clinic Patients. Journal of the Neurological Sciences 2004; 226: 97-98. 101. Rockwood KR, Black S, Gauthier S, and Feldman H. The Sub-Classification of Patients with Vascular Cognitive

Impairment by their Clinical Presentation and Radiographic Profile. Journal of the Neurological Sciences 2004; 226: 98.

102. Feldman H and Mackenzie IRA. Leptomeningeal and Superficial Cortical Hemosiderosis in Cerebral Amyloid

Angiopathy. Journal of the Neurological Sciences 2004; 226: 117. 103. Feldman H, Gauthier S, Hecker, J, Vellas B, Xu Y, Ieni J, and Schwam E. Donepezil shows significant benefits in

global function, cognition, ADL and behaviour in patients with severe Alzheimer's Disease (AD). European Journal of Neurology 2003 Sept.; 10 (Suppl. 1): 25.

50

104. Feldman H, Gauthier S, Hecker, J, Vellas B, Xu Y, Ieni J, and Schwam E. Donepezil shows benefits in patients with moderate to severe Alzheimer's disease (AD), independent of baseline severity. European Journal of Neurology 2003 Sept.; 10 (Suppl. 1): 158-159.

105. Feldman H. When do Behavioral Symptoms Become Manifest. International Psychogeriatrics 2003; 380. 106. Mackenzie IRA and Feldman H. Ubiquitin pathology suggests MND, MND-dementia and FTS-MND type represent

a clinicopathological spectrum. Brain Pathology 2003; S56. 107. Mackenzie IRA and Feldman H. Neuronal intranuclear inclusions distinguish familial FTD-MND type from

sporadic cases. Brain Pathology 2003; S58. 108. Yip S and Feldman H. Intractible Status Epilepticus Post Cartoid Endarterectomy – a clinical presentation of

cerebral hyperperfusion syndrome. Canadian Journal of Neurological Sciences 2003; 30(2): S78. 109. Feldman H, Gauthier SG, Hecker J, Vellas B, Xu Y, Ieni JR, and Schwam EM. Donepezil Shows Benefits in

Patient with Moderate to Severe AD Independent of Baseline Dementia Severity. Journal of the American Geriatrics Society 2003; 51(4): S52.

110. Feldman H, Spiegel R, and Quarg P. An evaluation of the effects of Rivastigmine on daily function in Alzheimer’s

disease at different levels of cognitive impairment. Neurology 2003; 60(S1): A142. 111. Gauthier S, Feldman H, Hecker J, Vellas B, Xu Y, Ieni JR, and Schwam EM. Donepezil shows significant benefits

in global function, cognition, ADL, and behavior in patients with severe Alzheimer’s disease. Neurology 2003; 60(S1): A413.

112. Hsiung G-YR, Field LL, Sadovnick DA, and Feldman H. Absence of Association of Interleukin-1A (IL1A) Gene

polymorphism with Alzheimer’s Disease (AD) in the Canadian Population. Neurology 2003; 60(S1): A454. 113. Feldman H, Gauthier S, Hecker J, Vellas, Emir B, and Subbiah P. Functional, Cognitive and Behavioral Benefits of

Donepezil in Patients with Moderate Alzheimer’s Disease. Journal of the American Geriatrics Society 2002; 50(4): S104-105.

114. Feldman H, Gauthier S, Hecker J, Vellas B, Emir B, Mastey V, and Subbiah P. Donepezil treatment benefits

caregivers of patients with moderate to severe Alzheimer’s disease (AD). European Journal of Neurology 2002; 9 (S2): 35.

115. Mackenzie IRA and Feldman H. Subcortical Ubiquitin Pathology in MND-Dementia and FTD-MND Type.

Neurobiology of Aging 2002; 23(1S): S59. 116. Mackenzie IRA and Feldman H. The relationship between extramotor ubiquitin-immunoreative neuronal inclusions

and dementia in motor neuron disease. Clinical Neuropathology 2002; 21: 171. 117. Mackenzie IRA, Feldman H. Subcortical ubiquitin pathology in MND-Dementia and FTD-MND Type. Journal of

Neuropathology & Experimental Neurology 2002; 61: 462. 118. Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, and Subbiah P. Exploratory Analysis of the Effects of

Donepezil in Moderate to Severe Alzheimer’s Disease Patients. Neurobiology of Aging 2002; 23(1S): S72. 119. Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Emir B, Subbiah P, and Mastey V. Improved Health Outcomes

with Donepezil in Moderate to Severe Alzheimer’s Disease are Associated with Economic Benefits. Neurobiology of Aging 2002; 23(1S): S74.

120. Feldman H, Scheltens P, Scarpini E, Hermann N, Ferris S, Mesenbrink P, Satlin A, and Mancione L. Behavioral

Symptoms in Mild Cognitive Impairment: Findings from the InDDEx Study. Neurobiology of Aging 2002; 23(1S): S138.

121. Ferris S, Feldman H, Mesenbrink P, Manicone L, and Satlin A. Mild Cognitive Impairment and Alzheimer’s

Disease: Are these Distinctive Study Populations for Clinical Trials? Neurobiology of Aging 2002; 23(1S): S152.

51

122. Rockwood K, MacKnight C, Black S, and Feldman H, Gauthier S, Hogan D, Vandorpe R, and Kertesz A. The

Consortium to Investigate Vascular Impairment of Cognition Methods and Impact of Diagnostic Criteria on the Study of Vascular Cognitive Impairment. Neurobiology of Aging 2002; 23(1S): S157.

123. Hsiung G-YR, Sadovnick D, Levy A, and Feldman H. Demographic Influences on Apolipoprotein E (APOE)

Polymorphism Distribution Among Patients with Alzheimer’s Disease (AD), Vascular Dementia, (VAD), and Cognitively Impaired Not Demented (CIND). Neurobiology of Aging 2002; 23(1S): S307.

124. Levy AR, Tam SP, Hsiung G-YR, and Feldman H. Use of Health Resources in a Canadian Collaborative Cohort

Study of Related Dementias (ACCORD). Neurobiology of Aging 2002; 23(1S): S549. 125. Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Emir B, Subbiah P, and Mastey V. Differences in Alzheimer’s

disease resource utilization across countries does not preclude pooling data in a multinational trial. Journal of Neurology 2002; 249(1): 14.

126. Buck B, de Feijter A, Mann S, Schulzer M, Feldman H, Beattie BL, and Lee CS. Visuospatial Construction Deficit

in Parkinson Disease and in Dementia with Lewy bodies is Associated with the Severity of Visual Hallucinations. Neurology 2002; 58(3): A436.

127. Hsiung G-YR, Johnston D, Donald A, and Feldman H for the ACCORD study group. An analysis of Vascular Risk

Factors and Apolipoprotein E /genotype in Subtypes of Dementia in the ACCORD Study. Neurology 2002; 58(3): A107.

128. Hsiung G-YR, Sadovnick AD, and Feldman H. Effect of Apolipoprotein E Genotype in Predicting Cognitive Decline

and Dementia among Different Ethnic Groups in Canada: Data from the Canadian Study of Health and Aging (CSHA). Neurology 2002; 58(3): A39.

129. Peters K, Scholes R, Donald A, and Feldman H. Characterizing Neuropsychiatric Symptoms in Cognitively–

Impaired-Not-Demented Subjects: Extending Phenotype Identification. Neurology 2002; 58(3): A276. 130. Feldman H, Levy AR and the ACCORD investigators. A Canadian Collaborative Study of Related Dementias

(ACCORD) – Description of the Cohort at Baseline. Canadian Society for Epidemiology and Biostatistics, Toronto, June 2001. American Journal of Epidemiology 2001; 153(11): S239.

131. Mackenzie IRA and Feldman H. Extrapyramidal Features in Patients with Motor Neuron Disease and Dementia: A

Clinopathological Correlative Study. Parkinsonism & Related Disorders 2001; 7: S30. 132. Mackenzie IRA and Feldman H. The relationship between extramotor ubiquitin-immunoreactive neuronal inclusions

and dementia in motor neuron disease. Journal of Neuropathology & Experimental Neurology 2001; 60: 547. 133. MacKenzie IRA and Feldman H. Ubiquitin Immunohistochemistry Suggests That Classical MND, MND With

Dementia and FTD-MND Type Represents a Clinicopathological Spectrum. Canadian Journal of Neurological Sciences 2000; 27(4): 348.

134. Howard KE, Kirkland SA, Montgomery PR, Hogan D, Feldman H, Black SE, and Rockwood K. Vascular Risk

Factor and Vascular Cognitive Impairment: What is the Relationship? Neurobiology of Aging 2000; 21(1S): S170. 135. Panisset M, Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, and Whalen E. Use of the Severe Impairment

Battery, in a Clinical Trial of Donepezil in Moderate to Severe Alzheimer’s Disease. Neurobiology of Aging 2000; 21(1S): S94.

52

136. Gauthier S, Feldman H, Hecker J, Vellas B, Subbiah P, and Whalen E. Efficacy of Donepezil on Neurobehavioral Symptoms in Patients with Moderate to Severe Alzheimer’s Disease. Journal of the American Geriatrics Society 2000; 48(8): S2 (A2).

137. Torfs K and Feldman H. 12-Month Decline in Cognitive and Daily Function in Patients with Mild-to-Moderate

Alzheimer’s Disease: Two Randomized, Placebo-Controlled Studies. Neurobiology of Aging 2000; 21(1S): S242-S243.

138. Sadovnick D, Yee I, and Feldman H. Apolipoprotein E Genotype as a Predictor or Progression from Cognitively

Impaired, But Not Demented to Dementia Over a 5-Year Period. Neurobiology of Aging 2000; 21(1S): S37. 139. Gauthier S, Feldman H, Hecker J, Vellas B, Subbiah P, and Whalen E. Benefits of Donepezil on Performance of

Basic and Instrumental Activities of Daily Living in Moderate to Severe Alzheimer’s Disease. Neurobiology of Aging 2000; 21(1S): S161.

140. Vellas B, Feldman H, Gauthier S, Hecker J, Subbiah P, and Whalen E. Donepezil Treatment in Patients With

Moderate to Severe Alzheimer’s Disease Reduces Caregiver Stress. Neurobiology of Aging 2000; 21(1S): S94. 141. Yee I, Feldman H, and Sadovnick D. The Effect of Apolipoprotein E Genotypes in Alzheimer’s Disease: Data from

the Canadian Study of Health and Aging. Neurobiology of Aging 2000; 21(1S): S36-S37. 142. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, and Whalen E. Donepezil Provides Benefits in Global

Function in Moderate to Severe Alzheimer’s Disease. Neurobiology of Aging 2000; 22(1S): S93. 143. Wentzel C, Black S, Feldman H, and Rockwood K. Outcomes of Dementia Treatment Using Patient-Centred,

Domain-Specific Visual Analogue Scales. Canadian Journal of Neurological Sciences 2000; 27(Suppl. 3): S46. 144. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, and Whalen E. Benefits of Donepezil on Global Function,

Behavior, Cognition and ADLs in Patients With Moderated to Severe Alzheimer’s Disease. Neurology 2000; 54(Suppl. 3): S79.003.

145. Donald A, Kertesz A, and Feldman H for the ACCORD Study Group. The Frontal Behavioral Inventory: An

Evaluation of its Diagnostic Utility for Frontotemporal Dementia. Neurology 2000; 54(Suppl. 3): S24.004. 146. Oger J, Wang L, Aziz T, and Feldman H. Is the Age of Onset of Myasthenia Gravis Increasing? An Analysis of the

Acetylcholine Receptor Antibody Assay Database of the Neuro-Immunology Laboratory at UBC. Canadian Journal of Neurological Sciences 1999; 26(Suppl. 1): S15.

147. Feldman, H, Donald A, and the ACCORD Study Group. A Comparative Study of the Canadian Study of Health and

Aging (CSHA) With a Canadian Cohort of Related Dementias (ACCORD) Study. Neurology 1999; 52(Suppl. 2): A431-432.

148. Gauthier S, Patterson C, Bergman H, Cohen C, Freightner J, Feldman H, Grek A, and Hogan D.

Recommendations from the Canadian Consensus Conference on Dementia. Annals of Neurology 1998; 44(3): 515. 149. Feldman H. Disease Stabilization - From Symptomatic to Disease Modifying Treatments. Neurobiology of Aging

1998; 19(Suppl. 4S): S76. 150. Jefferies W, Feldman H, Nurminen J, Levy D, Foti D, Kennard M, and Gabathuler R. Serum p97 Levels as a

Screening Test for Alzheimer’s Disease. Neurobiology of Aging 1998; 19 (Suppl. 4S): S82.

53

151. Feldman H, Kennard ML, Sauter AH, Tam S, Devonshire VA, Anderson DP, and Jefferies WA. Serum p97 Concentration but not Tropicamide Pupillary Response Identifies Alzheimer’s Disease. Neurology 1997; 48(Suppl. 2): S63.004.

152. Feldman H, Kennard M, Yamada T, Adams S, and Jefferies W. Serum Levels of the Iron Binding Protein p97: A

Novel Biological Marker of Alzheimer’s Disease. Neurobiology of Aging 1996; 17(Suppl. 4S): S169. 153. Feldman H, Green GJ, McGillivray BC, Berry K, Petersen RB, and Gambetti P. Fatal Familial Insomnia: A Chinese

Kindred With the 178 Aspargine Prion Protein Gene Mutation and 129 Methionine Homozygosity. Canadian Journal of Neurological Sciences 1996; 23(1): S47.

154. Feldman H, Mattman A, Schulzer M, Forster B, Li D, Amman W, and Beattie BL. An Assessment of Regional

Atrophy and Cerebral Blood Flow Utilizing HmPAO SPECT and CT Scanning for the Identification of Alzheimer’s Disease. Canadian Journal of Neurological Sciences 1995; 22(1): S50-S51.

155. Feldman H, Schulzer M, Wang S, Tuokko H, and Beattie BL. The Functional Rating Scale (FRS) in Alzheimer’s

Disease: A Longitudinal Study. Neurobiology of Aging 1994; 15(1): S8. 156. Feldman H, Weir J, Bell K, and Beattie BL. Extrapyramidal Signs (EPS) in Alzheimer’s Disease: Do They Predict

the Rate of Decline? Gerontologist 1993; 33: 176. 157. Tuokko H, Feldman H, Weir J, and Beattie BL. Single Photon Emission Computed Tomography Cerebral Activity,

Severity of Dementia and Duration of Symptomatology in Alzheimer Disease. Gerontologist 1991; 31: 176. PUBLISHED SCIENTIFIC ABSTRACTS (b) Conference Proceedings 1. Veroff AE, Perez M, Bertzos K, Brady C, Hazel J, Watson-Coleman O, Coric V, Berman R, Feldman HH ADAS-Cog

Central Monitoring and Intervention with Raters: A Critical Extension and Integral Component of Alzheimer's Trials Rater Training Programs. International Conference on Alzheimer’s Disease, Honolulu USA, July 2010.

2. Perez M; Bertzos K, Brady C, Hazel J, Watson-Coleman O, Berman R, Coric V, Feldman HH, Veroff AE; The

Relationship between Rater Experience and Performance on Certification Exercises and Study Subject Ratings in an Alzheimer’s Disease Trial. International Conference on Alzheimer’s Disease, Honolulu USA, July 2010.

3. Butler R, Beattie BL, Dwosh E, Feldman HH, Guimond C, Hsiung G-YR, Puangthong U, George-Hyslop P,

Rogaeva E, and Sadovnick AD. A novel PS1 mutation in a large aboriginal kindred with early onset familial Alzheimer Disease from a remote community in northern British Columbia. International Conference on Alzheimer’s Disease, Vienna, Austria, July 2009.

4. Feldman HH, Blaettler T, Berman RM, Han J, Kelleher T, and Marcus R. Assessing outcome measures for

prodromal AD clinical trials: A retrospective analysis from the ADNI database. International Conference on Alzheimer’s Disease, Vienna, Austria, July 2009.

5. Hsiung GR, Fok A, Feldman HH, Rademaker R, and MacKenzie IRA. Serum progranulin is reduced in GRN

mutation carriers but not in other dementia. International Conference on Alzheimer’s Disease, Vienna, Austria, July 2009.

6. Hsiung G-YR, Kupferschmidt AL, Naus K, Feldman HH, and Jacova C. Cognitive and clinical outcomes in a pilot

study using a handheld computer game for cognitive training of patients with mild cognitive impairment. International Conference on Alzheimer’s Disease, Vienna, Austria, July 2009.

54

7. Jacova C, Schulzer M, Money J, Deria S, Kupferschmidt AL, Beattie BL, and Feldman HH. Cross-sectional validation of a new instrument for the measurement of treatment response: the Clinical Meaningfulness in Alzheimer Disease Treatment (CLIMAT) scale. International Conference on Alzheimer’s Disease, Vienna, Austria, July 2009.

8. Jacova C, Schulzer M, Money J, Deria S, Kupferschmidt AL, Beattie BL, and Feldman HH. Social impact in the

measurement of clinically meaningful change: Findings from the cross-sectional validation of the Clinical Meaningfulness in Alzheimer Disease Treatment (CLIMAT) scale. International Conference on Alzheimer’s Disease, Vienna, Austria, July 2009.

9. Woodward M, Jacova C, Mackenzie IR, Feldman HH, Kertesz A, Black S, and the ACCORD Investigators.

Differentiating the frontal variant of Alzheimer’s disease. International Conference on Alzheimer’s Disease, Vienna, Austria, July 2009.

10. Hallam B, Jacova C, LaMarre A, Naus K, Sengdy P, Assaly M, Mackenzie IR, and Feldman HH. Executive control

of attention in presymptomatic progranulin-mutation carriers. 6th International Conference on Frontotemporal Dementia, Rotterdam. September 2008.

11. Ayoub OA, Grand J, Jacova C, Money J, Feldman HH, and Hsiung G-YR. Risk factors influencing survival in

Alzheimer’s disease: Analysis from a single center in the Canadian Cohort Study of Cognitive Impairment and Related Dementias (ACCORD). International Conference on Alzheimer’s Disease, July 2008.

12. Jacova C, Kandiah N, Schulzer M, and Feldman HH. Quality of life in mild cognitive impairment that does not

progress to Alzheimer disease: Longitudinal analysis of the InDDEx study. International Conference on Alzheimer’s Disease, July 2008.

13. Kandiah N, Jacova C, Schulzer M, and Feldman HH. Longitudinal change in cognition and activities of daily living

among subjects with stable mild cognitive impairment: The InDDEx study. International Conference on Alzheimer’s Disease, July 2008.

14. Hsiung G-Y, Ayoub O, Money J, Jacova C, and Feldman H. Survival analysis of patients with cognitive impairment

and subtypes of dementia from a specialized dementia clinic. 60th annual meeting of the American Academy of Neurology, April 2008.

15. Pfeffer G, Yeo J, Jacova C, Oelech S, and Feldman HH. Protein expression profiles from blood lymphocytes can

distinguish patients with Alzheimer Disease from age-matched controls. 60th annual meeting of the American Academy of Neurology, April 2008.

16. Feldman H. MCI and Alzheimer’s disease. 18th meeting of the European Neurological Society, Nice, France. June

2008. 17. Brooks BL, Iverson GL, Holdnack JA, and Feldman HH. Psychometric Misdiagnosis of Amnestic MCI in Healthy

Older Adults: Part I. WMS-III Primary and Index Scores. 27th annual conference of the National Academy of Neuropsychology. Scottsdale, AZ. November 2007.

18. Brooks BL, Iverson GL, Holdnack JA, and Feldman HH. Psychometric Misdiagnosis of Amnestic MCI in Healthy

Older Adults: Part II. An Abbreviated WMS-III Battery. 27th annual conference of the National Academy of Neuropsychology. Scottsdale, AZ. November, 2007.

19. Hsiung G-YR, Alipour S, Jacova C, and Feldman HH. Transition from Cognitive Impairment Not Dementia to

Alzheimer’s Disease: An analyses of changes in functional abilities. 59th annual meeting of the American Academy of Neurology, April 2007.

20. Hsiung G-YR, Rockwood K, and Feldman H for the ACCORD Investigators Group. Presence of Leukoaraiosis and

diffuse Brain Atrophy predicts progression of Cognitively Impaired Not Demented (CIND) to Dementia. 2nd Congress of the International Society for Vascular Behavioural and Cognitive Disorders (VAS-COG). 2005: 19.

21. Rockwood K, Black S, and Feldman H. Progression to dementia in patients with vascular cognitive impairment

without dementia: a multi-centre clinical study. 2nd Congress of the International Society for Vascular Behavioural and Cognitive Disorders (VAS-COG). 2005: 105.

55

22. Feldman H, Van Baelen B, and Kavanagh S. Galantamine Delays Admission to Nursing Home.

(Montreal/Springfield Symposium on Advances in Alzheimer Therapy). Neurobiology of Aging 2004; 25(S1): S9. 23. Feldman H, Gauthier S, Hecker J, Vellas J, Hux M, Shah SN, Xu Y, Schwam E, and Leaderer M. Donepezil in

severe Alzheimer's disease: an economic analysis. Alzheimer Disease International Conference 2004. 24. Feldman H, Gauthier S, Hecker J, Vellas J, Xu Y, Leni J, and Schwam E. Donepezil produces significant benefits

on measures of daily function, social interaction, and caregiver time in severe Alzheimer's disease patients. Alzheimer Disease International Conference 2004.

25. Lescrauwaet B, Charbonneau C, Lauzon V, Donald A, and Feldman H. The Impact of Donepezil (DPZ) on the Cost

of Alzheimer’s Disease (AD). Meeting of the Canadian Association for Population Therapeutics (CAPT) 2004. 26. Feldman H, Kavanagh S, and Van Baelen B. Effect of galantamine on time to residential or nursing home

admission. Meeting of the European Federation of Neurological Societies (EFNS) 2004. 27. Feldman H, Gauthier SG, Hecker J, Vellas B, Xu Y, Leni J, and Schwam E. Donepezil has significant functional

and behavioral benefits in patients with severe Alzheimer's disease. European College of Neuropsychopharmacology (ECNP): Annual Meeting 2003; 13 (Suppl. 4): P4040.

28. Lee C, Zamburlini M, Sossi V, Holden JE, Adam MJ, Beattie BL, Feldman H, Mackenzie IR, Stoessl AJ, and Ruth

TJ. Cholinergic and Dopaminergic Deficits in Parkinson's disease, Dementia with Lewy Bodies and Alzheimer's disease: in vivo PET studies. Dementia with Lewy Bodies and PD Dementia 3rd International Workshop. Newcastle, UK. September 2003.

29. Feldman H. The impact of galantamine on the incidence of behavioral disturbances in patients with dementia. 43rd

Annual New Clinical Drug Evaluation Unit (NCDEU) meeting. Boca Raton, FL. May 2003. 30. Feldman H, Lilienfeld S, and Mahableshwarkar A. The effect of galantamine on behavior: Maintenance of effects

with treatment in vascular dementia and Alzheimer’s disease with cerebrovascular disease. American Psychiatric Association Annual Meeting. San Francisco, CA. May 2003.

31. Feldman H, Gauthier S, Vellas B, Hecker J, Xu Y, Jeni J, and Schwam E. Donepezil has significant benefits on

behavior in patients with severe Alzheimer’s disease. American Psychiatric Association Annual Meeting. San Francisco, CA. May 2003.

32. Cochrane L, Feldman H, Murray S, Hayes S, McEachern B, and Maurais JA. Understanding Physicians’ Barriers in

the Care of Dementia. Alzheimer Society of Canada 25th National Conference. Ottawa, ON. April 2003. 33. Peters K, Graf P, Hayden S, and Feldman H. Neuropsychological Subgroups of Cognitively-Impaired-Not-

Demented Individuals. Canadian Society for Brain, Behaviour, and Cognitive Science. Vancouver, BC. June 2002. 34. Feldman H. Behavioral Disturbances in Dementia: A Continuum of Symptoms and Treatment Options. The 15th

Annual Meeting of the American Association for Geriatric Psychiatry. Florida. February 2002. 35. Lee CS, De Feijter A, Mann S, Scholes R, Feldman H, Beattie BL, Schulzer M. Visuospatial Impairment is More

Pronounced in Parkinson’s Disease than in Alzheimer’s Disease and Associated with both the Severity of Hallucinations and Parkinsonian Motor Symptoms. International Symposium on Mental and Behavioural Dysfunction in Movement Disorders. Montreal, PQ. October 2001.

36. Feldman H. Moderate to Severe AD; A Treatable Disease Stage? A View From the MSAD Study. 23rd National

Conference and Annual General Meeting. Alzheimer’s Society of Canada. Halifax, NS. 2001. 37. Feldman H. Vascular Risk Factors in Relation to Common Vascular and Neurodegenerative Dementias. The

XV11th World Congress of the International Association of Gerontology. Vancouver, BC. July 2001.

56

38. Feldman H. The Emerging Spectrum of Cholinesterase Inhibitor Therapy for Alzheimer’s Disease. 45th Annual Congress of the Italian Society of Gerontology and Geriatrics. Florence, Italy. November 2000.

39. Feldman H, Gauthier S, Hecker J, Subbiah P, and Whalen E. Benefici del donezepil sulla funzione globale, il

comportamento, la sfera cognitiva e le attività del vivere quotidiano in pazienti affetti da malattia de Alzheimer moderato-severa. 45th Annual Congress of the Italian Society of Gerontology and Geriatrics. Florence, Italy. November 2000.

40. Clement J, Forster BB, Brief E, McKay A, Vernon-Wilkinson R, Scamvougeras A, and Feldman H. Can MRI/MRS

Predict the Extent of Head Injury in Chronic Brain Injury Patients? Canadian Association of Radiologists Meeting. Toronto, ON. June 2000.

41. Gauthier S, Feldman H, Vellas B, and Whalen E. Donepezil Improves Neuropsychiatric Symptoms in Moderate to

Severe Alzheimer’s Disease. 153rd Annual Meeting of the American Psychiatric Association. Chicago, IL. May 2000.

42. Brief E, Vernon-Wilkinson R, MacKay AL, Scamvougeras A, Feldman H, and Forster B. 1H MRS, MRI and

Neuropathological Testing of Patients With Traumatic Brain Injury at Long Elapsed Time Since Injury. Eighth Meeting of the International Society for Magnetic Resonance in Medicine. Denver, CO. April 2000.

43. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, and Whalen E. Donepezil’s Benefits on Cognition, Global

Function, Activities of Daily Living and Behavior in Patients with Moderate to Severe Alzheimer’s Disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. Stockholm, Sweden. April 2000.

44. Feldman H. Therapeutic Benefits of Acetylcholinesterase Inhibitor Therapy in the Moderate to Severe Stages of

Alzheimer’s Disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. Stockholm, Sweden. April 2000.

45. Feldman H, Donald A. Functional Changes as a Marker of Disease Progression in Alzheimer Disease. Ninth

Congress of the International Psychogeriatric Association. Vancouver, BC. August 1999. 46. Feldman H, Donald A, and the ACCORD Study Group. Diagnostic Classification Issue in AD Prevention Trials.

Ninth Congress of the International Psychogeriatric Association. Vancouver, BC. August 1999. 47. Feldman H. Dementia, Treatment and Ethics, 34th Meeting of the Canadian Congress of Neurological Sciences,

Edmonton, AB. June 1999. 48. Feldman H. Initiating and Continuing Treatment for AD. International Symposium on Current Developments and

Future Strategies in Alzheimer’s Disease. Barcelona, Spain. March 1999. 49. Feldman H. Caregiver Burden: A Key Concept in AD Management. 15th International Geneva Symposium on

Advances in Alzheimer Therapy. Geneva, Switzerland. April 1998. 50. Anand R, Feldman H, Thal HJ, and Hardy J. New Treatment Horizons in Alzheimer’s Disease. 13th International

Conference of Alzheimer’s Disease. Helsinki, Finland. October 1997. 51. Feldman H, Donald A, Sauter A, and Parys WA. A Protocol to Evaluate Pharmacoeconomics in a Clinical Trial.

13th International Conference and 7th Annual European Meeting. Helsinki, Finland. October 1997. 52. Feldman H. Managing the Burden: Care for the AD Patient. Eighth Congress of the International Psychogeriatric

Association. Jerusalem, Israel. August 1997. 53. Feldman H. The Health Economy of Dementia: Symposium. Eighth Congress of the International Psychogeriatric

Association. Jerusalem, Israel. August 1997. 54. Solomons K, Cooney T, Beach T, and Feldman H. Neuroleptic Malignant Syndrome and Dementia with Lewy

Bodies: A Case Report. Progress in Alzheimer’s and Parkinson’s Diseases. Fourth International Conference. Eilat, Israel. May 1997.

57

55. Fleming JAE, Feldman H, Green GJ, McGillivray BC, Kang A, and Berry K. Non-response of a Case of Fatal

Familial Insomnia to Gamma Hydroxy Butyrate. Association of Professional Sleep Societies Meeting. Washington. DC. June 1996.

56. Feldman H, for the Translation Committee of the International Working Group on Harmonization of Dementia Drug

Guidelines. Translation Issues in International Dementia Clinical Trials. 4th International Nice/Springfield Symposium on Advances in Alzheimer Therapy. Nice, France. April 1996.

57. O’Rourke N, Feldman H, Tuokko H, Katrynuik T, and Beattie BL. Patterns of Service Utilization Within a

Representative Canadian Sample of Dementia Patients and Their Caregivers. The Seventh International Psychogeriatric Conference. Sydney, Australia. October 1995.

58. Feldman H, Sauter A, Devonshire V, Anderson D, Beattie BL, and Schulzer M. Tropicamide: A Potential Diagnostic

Test for Alzheimer’s Disease. Canadian Association on Gerontology. Vancouver, BC. October 1995. 59. Gauthier S, Feldman H, and Mohr E. Minimal Efficacy Criteria for Drugs in Alzheimer’s Disease, Including

Pharmaco-Economic Consideration. The 3rd International Symposium on Advances in Alzheimer Therapy. Springfield, IL. 1994.

60. Gauthier S, Montplaisir J, Joanette Y, Feldman H, Mohr E, Nair NPV, and Poirier J. Outcome Variables in Pre-

Symptomatic Individuals at High Risk of Developing Alzheimer disease. National Institute on Aging, Alzheimer Disease Research Planning Meeting III. Washington, DC. 1994.

61. Feldman H. Alzheimer’s Disease - the Caregiver Burden. Alzheimer’s Disease International Meeting, 13th

International Conference. October 1992. BOOKS 1. Feldman HH (Editor). Atlas of Alzheimer’s Disease & Dementia. Informa Health, Ltd., London. 2007. CHAPTERS WITHIN BOOKS

1. Feldman HH. The Dementias: An Overview. International Neurology: A Clinical Approach. Wiley-Blackwell

Publishing, Oxford, UK. 2009. 2. Jacova C and Feldman HH. Mild Cognitive Impairment. New Oxford Textbook of Psychiatry (2nd Ed.). Ed. Gelder M,

Lopez-Ibor J, Andreasen N, and Geddes J. Oxford University Press, Oxford, UK. 2009. 3. Feldman HH and Yeo LHJ. Pharmacological Strategies in the Treatment of Alzheimer’s Disease. Fundacion

Ramon Areces. Spain. 2007. 4. Woodward M and Feldman H. Management – Mild to Moderate Stages. Ed Gauthier S. Clinical Diagnosis and

Management of Alzheimer’s Disease. 3rd Ed. Taylor & Francis, Ltd., London. 2006. 5. Woodward M and Feldman H, Drug Treatment: Cholinesterase Inhibitors. Severe Dementia. John Wiley & Sons,

Ltd., London. 2006. 6. Feldman H, Van Baelen B, and Kavanagh S. Effects of Galantamine on Activities of Daily Living in Alzheimer’s

Disease: evidence from six randomised double-blind placebo-controlled trials. Research and Practice in Alzheimer’s Disease. Serdi Publishier, Paris. 2005; Vol. 10: 229-233.

58

7. Winblad B and Feldman H. Consensus on Severe Dementia: EADC-ADCS. Research and Practice in Alzheimer’s Disease. Serdi Publisher, Paris. 2005; Vol. 10: 59-80.

8. Hsiung R and Feldman H. Therapeutics options: Donepezil. Alzheimer’s Disease: A Physician’s Guide to Practical

Management. Ed. Richter R. and Richter B., Humana Press, New Jersey. 2003. 9. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E, and Emir B. The Efficacy and Safety of

Donepezil in Patients with Moderate to Severe Alzheimer’s Disease. Research and Practice in Alzheimer’s Disease. Ed. Vellas B. Springer Publishing Company, New York, Serdi Publisher, Paris. 2002; 6.

10. Rockwood K, Black S, Gauthier S, Feldman H, and Wentzel C. Clinical and Neuroimaging Findings in Mixed

Dementia. Research and Practice in Alzheimer’s Disease. Eds, Vellas B, Winblad B, Grundman MN, Fitten LJ, Feldman H, Giacobini E. Springer Publishing Company, New York, Serdi Publisher, Paris. 2001; 5: 115-122.

11. Feldman H and Grundman M. Symptomatic Treatments for Alzheimer's Disease. Ed. Gauthier S. Clinical

Diagnosis and Management of Alzheimer's Disease. 2nd Ed. London, Martin Dunitz. 1999; 249-268. 12. Feldman H and O’Brien JT. Differentiation of the Common Dementias. In Diagnosis and Management of Dementia:

A Manual for Memory Disorders Teams. Eds. By Wilcock G, Rockwood K, Bucks R. Oxford, Oxford University Press. 1998; 231-251.

13. Feldman H, Solomons K, Cooney T, et al. Neuroleptic Malignant Syndrome and Dementia With Lewy Bodies: A

Case Study. In: Progress in Alzheimer's and Parkinson's Diseases. Ed. Fisher et al. New York, Plenum Press. 1998; 351-358.

14. Feldman H and Prigent B. Clinical and Economic Considerations of Antidementia Drug Treatment. Eds. Wimo A,

Jonsson B, Karlsson G, Winblad B. Health Economics of Dementia, Chichester, U.K. John Wiley & Sons Ltd. 1998; 501-516.

15. Feldman H. Treatment of Vascular Cognitive Impairment/Vascular Dementia. Ancill RJ, Holliday SG, Mithani AH.

Eds. Therapeutics in Geriatric Psychiatry: John Wiley & Sons Ltd. 1997; 13-30. 16. Feldman H, Kennard M, Yamada T, Adams S, Jand efferies W. Serum Levels of the Iron Binding Protein p97: A

Novel Biological Marker of Alzheimer’s Disease. Iqbal K, Winblad B, Nishimura T. Takeda M, Wisniewski HM, Eds. Chichester, England: J Wiley & Sons Ltd. 1997; 189-196.

17. Feldman H and Gracon S. Alzheimer’s Disease: Symptomatic Drugs Under Development. In: Clinical Diagnosis

and Management of Alzheimer’s Disease. Ed. Gauthier SG. London, UK: Martin Dunitz. 1996; 239-259. 18. Feldman H and Beattie BL. Long-Term Cognitive Therapy for Alzheimer’s Disease. Ancill RJ & Lader MH Eds.

Bailliere's Clinical Psychiatry: Pharmacological Management of Chronic Psychiatric Disorders. London UK: Bailliere Tindall. 1995; 639-655.

19. Feldman H, Schulzer M, Wang S, Tuokko H, and Beattie BL. The Functional Rating Scale (FRS) in Alzheimer’s

Disease: A Longitudinal Study. Iqbal K, Mortimer J, Winbald B, Wisniewski H, Eds. Research Advances in Alzheimer’s Disease and Related Disorders. Chichester, England: J Wiley & Sons Ltd. 1995; 235-241.

20. Gauthier S, Feldman H, and Mohr E. Minimal Efficacy Criteria for Drugs in Alzheimer’s Disease, Including

Pharmaco-Economic Considerations. Giacobini E & Becker R, Eds. Alzheimer’s Disease: Therapeutic Strategies. Boston, Birkhauser. 1994; 431-435.

59

PATENTS

1. Feldman HH (Filed November 26, 2008). Detecting and Treating Dementia Serial Number 12/302,691

U.S. Patent No. PCT/US2007/07008. Washington, DC: U.S. Patent and Trademark Office.

OTHER WORKS

1. Editor - Synapse Publishing, Dementia Guidance System: 1997 - 1999 (on line publishing)

2. Editor - Neuronet, Dementia Section: 1996 - 1998 (on line publishing)

3. Editor in Chief - Carma Publishing 2007 (on line publishing)

Documents

THE UNIVERSITY OF BRITISH COLUMBIA€¦ · UBC CME Program: Update on the Dementia Syndrome – January 18, 2003 17. Vancouver General Hospital: Neuroscience Grand Rounds – September